A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer

A Double-Blind, Placebo-Controlled, Randomized, Multicenter Phase III Study Evaluating the Efficacy and Safety of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Metastatic Gastroesophageal Junction and Gastric Cancer

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01774786

Acronym

JACOB

Enrollment

780

Registered

2013-01-24

Start date

2013-06-10

Completion date

2019-12-31

Last updated

2020-12-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer

Brief summary

This double-blind, placebo-controlled, randomized, multicenter, international, parallel arm study will evaluate the efficacy and safety of pertuzumab in combination with trastuzumab, fluoropyrimidine and cisplatin as first-line treatment in participants with HER2-positive metastatic gastroesophageal junction (GEJ) or gastric cancer (GC). Participants will be randomized to receive pertuzumab 840 milligrams (mg) or placebo intravenously every 3 weeks (q3w) in combination with trastuzumab (initial dose of 8 milligrams per kilogram \[mg/kg\] intravenously \[IV\] followed by 6 mg/kg IV q3w) and cisplatin and fluoropyrimidine (capecitabine or 5-fluorouracil) for the first 6 treatment cycles. Participants will continue to receive pertuzumab or placebo and trastuzumab until disease progression occurrence of unacceptable toxicity or withdrawal from the study for another reason.

Interventions

DRUG5-Fluorouracil

Participants will receive 5-fluorouracil 800 milligrams per meter square (mg/m\^2)/24 hour IV infusion for 120 hours (Days 1-5) q3w for 6 cycles.

DRUGCapecitabine

Participants will receive capecitabine 1000 mg/m\^2 orally twice daily, evening of Day 1 to morning of Day 15 (28 doses) q3w for 6 cycles.

DRUGCisplatin

Participants will receive cisplatin 80 mg/m\^2 IV q3w for 6 cycles.

DRUGPertuzumab

Participants will receive pertuzumab 840 mg IV q3w until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.

DRUGPlacebo

Participants will receive placebo (matched to pertuzumab) IV q3w until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.

DRUGTrastuzumab

Participants will receive 8 mg/kg IV initial dose on Day 1, followed by 6 mg/kg IV q3w until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Histologically confirmed metastatic adenocarcinoma of the stomach or GEJ * Measurable or evaluable non-measurable disease as assessed by the investigator according to RECIST v1.1 criteria * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 * Life expectancy greater than equal to (\>/=) 3 months

Exclusion criteria

* Previous cytotoxic chemotherapy for advanced (metastatic) disease * Evidence of disease progression documented within 6 months after completion of prior neoadjuvant or adjuvant cytotoxic chemotherapy, or both, or radiotherapy for GEJ adenocarcinoma * Previous treatment with any HER2-directed therapy, at any time, for any duration * Previous exposure to any investigational treatment within 30 days before the first dose of study treatment * Radiotherapy within 30 days before the first dose of study treatment (within 2 weeks if given as palliation to bone metastases, if recovered from all toxicities) * History or evidence of brain metastases * Clinically significant active gastrointestinal (GI) bleeding (Grade \>/=2 according to National Cancer Institute \[NIC\]-Common Terminology Criteria for Adverse Events Version 4.0 \[CTCAEv.4.0\]) * Residual toxicity resulting from previous therapy (for example, hematologic, cardiovascular, or neurologic toxicity that is Grade \>/=2). Alopecia is permitted * Other malignancy (in addition to gastric cancer \[GC\]) within 5 years before enrollment, except for carcinoma in situ of the cervix or squamous or basal cell carcinoma of the skin that has been previously treated with curative intent * Inadequate hematologic, renal or liver function * Pregnant or lactating women * History of congestive heart failure of any New York Heart Association (NYHA) criteria * Angina pectoris requiring treatment * Myocardial infarction within the past 6 months before the first dose of study drug * Clinically significant valvular heart disease or uncontrollable high-risk cardiac arrhythmia * History or evidence of poorly controlled hypertension * Baseline left ventricular ejection fraction (LVEF) value less than (\<) 55 percent (%) * Any significant uncontrolled intercurrent systemic illness * Positive for hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection

Design outcomes

Primary

Measure	Time frame	Description
Overall Survival	From Baseline until death from any cause (Median [full range] duration of follow-up in Pertuzumab vs. Placebo arms for Primary Analysis: 24.4 [0-42] months vs. 25.0 [0-41] months; Final Analysis: 46.1 [0-70] months vs. 44.4 [0-68] months)	Overall survival (OS) was defined as the time from randomization to death from any cause. For participants who were still alive on the date of clinical data cut-off for the OS analysis, the last date when the participant was known to be alive on, or prior to the clinical cut-off date, was used to determine the censoring date. Participants who did not have any post-baseline data (e.g., dosing records, imaging dates, visit dates) were censored at the date of randomization plus 1 day.

Secondary

Measure	Time frame	Description
Primary Analysis of the Percentage of Participants With Overall Objective Response, as Determined by the Investigator According to RECIST v1.1 Criteria	Baseline up to death or progressive disease, whichever occurred first (Median [full range] duration of follow-up in Pertuzumab vs. Placebo arms for Primary Analysis: 24.9 [0-41] months vs. 21.3 [0-39] months)	The overall objective response rate was defined as the percentage of participants with partial response (PR) or complete response (CR) occurring on two consecutive occasions ≥4 weeks apart, as determined by the investigator using RECIST v1.1. Tumor assessments with computed tomography (CT) or magnetic resonance imaging (MRI) scans of the chest, abdomen, and pelvis were performed every 9 weeks. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR: disappearance of all target lesions. Measurable disease is defined as tumor lesions measured in at least one dimension (longest diameter in plane of measurement) with a minimum size of: 10 mm by CT or MRI scan; 10 mm caliper measurement by clinical examination; 20 mm by chest X-ray. For a malignant lymph node to be considered pathologically enlarged and measurable, it must be greater than or equal to (≥) 15 mm in short axis when assessed by CT scan.
Final Analysis of the Percentage of Participants With Overall Objective Response, as Determined by the Investigator According to RECIST v1.1 Criteria	Baseline up to death or progressive disease, whichever occurred first (Median [full range] duration of follow-up in Pertuzumab vs. Placebo arms for Final Analysis: 50.4 [0-70] months vs. 47.4 [0-66] months)	The overall objective response rate was defined as the percentage of participants with partial response (PR) or complete response (CR) occurring on two consecutive occasions ≥4 weeks apart, as determined by the investigator using RECIST v1.1. Tumor assessments with computed tomography (CT) or magnetic resonance imaging (MRI) scans of the chest, abdomen, and pelvis were performed every 9 weeks. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR: disappearance of all target lesions. Measurable disease is defined as tumor lesions measured in at least one dimension (longest diameter in plane of measurement) with a minimum size of: 10 mm by CT or MRI scan; 10 mm caliper measurement by clinical examination; 20 mm by chest X-ray. For a malignant lymph node to be considered pathologically enlarged and measurable, it must be greater than or equal to (≥) 15 mm in short axis when assessed by CT scan.
Duration of Objective Response, as Determined by Investigator According to RECIST v1.1 Criteria	Baseline to death or progressive disease (PD), whichever occurred first (Median [full range] duration of follow-up in Pertuzumab vs. Placebo arms for Primary Analysis: 24.9 [0-41] vs. 21.3 [0-39] months; Final Analysis: 50.4 [0-70] vs. 47.4 [0-66] months)	Duration of objective response is defined as the time from first occurrence of documented objective response to documented disease progression, as determined by the investigator using RECIST v1.1, or death from any cause. Objective response: PR or CR occurring on 2 consecutive occasions ≥4 weeks apart. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR: disappearance of all target lesions. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline; an absolute increase of at least 5 mm in the sum of diameters of target lesions; the appearance of one or more new lesions. Measurable disease defined as tumor lesions with a minimum size of: 10 mm by CT or MRI scan; 10 mm caliper measurement by clinical examination; 20 mm by chest X-ray. For a malignant lymph node, it must be ≥15 mm in short axis when assessed by CT scan.
Percentage of Participants With Clinical Benefit, as Determined by the Investigator According to RECIST v1.1 Criteria	Baseline up to death or progressive disease, whichever occurred first (Median [full range] duration of follow-up in Pertuzumab vs. Placebo arms for Primary Analysis: 24.9 [0-41] months vs. 21.3 [0-39] months)	The clinical benefit rate was defined as best response of complete response (CR) or partial response (PR) or stable disease (SD) for 6 weeks or longer, as determined by the investigator using RECIST v1.1. CR: disappearance of all target lesions. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression, taking as reference the smallest sum diameters while on study. Measurable disease is defined as tumor lesions measured in at least one dimension (longest diameter in plane of measurement) with a minimum size of: 10 mm by CT or MRI scan; 10 mm caliper measurement by clinical examination; 20 mm by chest X-ray. For a malignant lymph node to be considered pathologically enlarged and measurable, it must be \>/=15 mm in short axis when assessed by CT scan. The clinical benefit rate was not updated at the final analysis.
Overview of Safety: Number of Participants With at Least One Adverse Event, Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.03	From Baseline until end of post-treatment follow-up (up to 70 months)	An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. The investigator graded all AEs for severity per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.03; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE.
Number of Participants With Symptomatic or Asymptomatic Left Ventricular Systolic Dysfunction (LVSD)	From Baseline until end of post-treatment follow-up (up to 70 months)	The number and percentage of participants with symptomatic left ventricular systolic dysfunction (LVSD) and asymptomatic LVSD events (defined as a left ventricular ejection fraction \[LVEF\] ≥10% decrease from baseline to an absolute value \<50%) at any time during the study was summarized by treatment arm.
Progression-Free Survival, as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Criteria	Baseline to death or progressive disease (PD), whichever occurred first (Median [full range] duration of follow-up in Pertuzumab vs. Placebo arms for Primary Analysis: 24.9 [0-41] vs. 21.3 [0-39] months; Final Analysis: 50.4 [0-70] vs. 47.4 [0-66] months)	Progression-free survival (PFS) is defined as the time from randomization to the first occurrence of progressive disease (PD), as determined by the investigator using RECIST v1.1, or death from any cause, whichever occurred first. Tumor assessments with CT or MRI scans of the chest, abdomen, and pelvis were performed every 9 weeks. Participants without documented PD or death were censored at the tumor assessment date for which the participant was last known to be progression-free. Participants who did not have any post-baseline tumor assessment data were censored at the date of randomization plus 1 day. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline; an absolute increase of at least 5 millimeters (mm) in the sum of diameters of target lesions; the appearance of one or more new lesions.
Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Day 1 of each 21-day treatment cycle up to 28 and 60-90 days (post-treatment [PT] monitoring visits 1 and 2, respectively) after Day 1 of last treatment cycle (up to approximately 3.5 years)	The EORTC QLQ-C30 included global health status, functional scales (physical, role, emotional, cognitive, and social), symptom scales (fatigue, nausea/vomiting, and pain) and single items (dyspnoea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Most questions used a 4-point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale \[1 'very poor' to 7 'Excellent'\]). Scores were averaged and transformed to 0 - 100 scale, whereby higher scores indicate greater functioning, greater quality of life, or a greater degree of symptoms, with changes of 5 - 10 points considered to be a minimally important difference to participants. A positive value means an increase, while a negative value means a decrease, in score at the indicated time-point relative to the score at baseline (Cycle 1, Day 1).
Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Day 1 of each 21-day treatment cycle up to 28 and 60-90 days (post-treatment [PT] monitoring visits 1 and 2, respectively) after Day 1 of last treatment cycle (up to approximately 3.5 years)	The EORTC QLQ-STO22 is a gastric cancer quality of life questionnaire. There are 22 questions concerning disease, treatment related symptoms, side effects, dysphagia, nutritional aspects, and questions about the emotional problems of gastric cancer (dysphagia, pain, reflux, eating restrictions, anxiety, dry mouth, body image, and hair loss). The questions are grouped into five scales and 4 single items which are related to the symptoms of the disease. Most questions used 4-point scale (1 'Not at all' to 4 'Very much'; 1 question was a yes or no answer). A linear transformation was used to standardize all scores and single-items to a scale of 0 to 100; higher score=better level of functioning or greater degree of symptoms. A positive value means an increase, while a negative values means a decrease, in score at the indicated time-point relative to the score at baseline (Cycle 1, Day 1).
Maximum Serum Concentration (Cmax) of Pertuzumab	Post-dose (0.5 hour after end of 30-60 minutes infusion) on Day 1 of Cycles 1, 2, 4, and 8 (1 cycle = 21 days)	—
Cmax of Trastuzumab	Post-dose (0.5 hour after end of 30-60 minutes infusion) on Day 1 of Cycles 1, 2, 4, and 8 (1 cycle = 21 days)	—
Cmin of Trastuzumab	Pre-dose (0-6 hours before infusion) on Day 1 of Cycles 1, 2, 3, 4, 6, and 8 (1 cycle = 21 days)	—
Minimum Serum Concentration (Cmin) of Pertuzumab	Pre-dose (0-6 hours before infusion) on Day 1 of Cycles 1, 2, 3, 4, 6, and 8 (1 cycle = 21 days)	—

Countries

Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Croatia, El Salvador, Finland, Germany, Guatemala, Hungary, Italy, Japan, Kazakhstan, Malaysia, Mexico, Netherlands, North Macedonia, Panama, Peru, Poland, Romania, Russia, South Korea, Spain, Switzerland, Taiwan, Thailand, Turkey (Türkiye), United States

Participant flow

Pre-assignment details

A total of 780 participants were enrolled in the study.

Participants by arm

Arm	Count
Pertuzumab + Trastuzumab + Chemotherapy Participants received pertuzumab in combination with trastuzumab and chemotherapy (cisplatin and fluoropyrimidine \[capecitabine or 5-fluorouracil\]) for the first 6 treatment cycles (cycle length = 21 days). Thereafter, participants continued to receive pertuzumab and trastuzumab until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.	388
Placebo + Trastuzumab + Chemotherapy Participants received placebo in combination with trastuzumab and chemotherapy (cisplatin and fluoropyrimidine \[capecitabine or 5-fluorouracil\]) for the first 6 treatment cycles (cycle length = 21 days). Thereafter, participants continued to receive placebo and trastuzumab until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.	392
Total	780

Withdrawals & dropouts

Period	Reason	FG000	FG001
Overall Study	Death	300	319
Overall Study	Lost to Follow-up	6	7
Overall Study	Non-compliance	0	1
Overall Study	Physician Decision	2	0
Overall Study	Reason Not Specified	2	5
Overall Study	Withdrawal by Subject	18	14

Baseline characteristics

Characteristic	Placebo + Trastuzumab + Chemotherapy	Total	Pertuzumab + Trastuzumab + Chemotherapy
Age, Continuous	60.1 Years STANDARD_DEVIATION 10.7	60.5 Years STANDARD_DEVIATION 11	60.9 Years STANDARD_DEVIATION 11.3
Geographic Region Asia (excluding Japan)	146 Participants	289 Participants	143 Participants
Geographic Region Japan	40 Participants	80 Participants	40 Participants
Geographic Region North America/Western Europe/Australia	133 Participants	266 Participants	133 Participants
Geographic Region South America/Eastern Europe	73 Participants	145 Participants	72 Participants
Human Epidermal Growth Factor Receptor 2 (HER2) Status IHC 2+/ISH+	130 Participants	259 Participants	129 Participants
Human Epidermal Growth Factor Receptor 2 (HER2) Status IHC 3+	262 Participants	521 Participants	259 Participants
Measurability of Disease, per RECIST v1.1 Measurable Disease	352 Participants	703 Participants	351 Participants
Measurability of Disease, per RECIST v1.1 Non-Measurable Evaluable Disease Only	40 Participants	77 Participants	37 Participants
Prior Gastrectomy No Prior Gastrectomy	290 Participants	573 Participants	283 Participants
Prior Gastrectomy Prior Gastrectomy	102 Participants	207 Participants	105 Participants
Sex: Female, Male Female	69 Participants	163 Participants	94 Participants
Sex: Female, Male Male	323 Participants	617 Participants	294 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk
deaths Total, all-cause mortality	299 / 385	318 / 388
other Total, other adverse events	373 / 385	376 / 388
serious Total, serious adverse events	178 / 385	156 / 388

Outcome results

Primary

Overall Survival

Overall survival (OS) was defined as the time from randomization to death from any cause. For participants who were still alive on the date of clinical data cut-off for the OS analysis, the last date when the participant was known to be alive on, or prior to the clinical cut-off date, was used to determine the censoring date. Participants who did not have any post-baseline data (e.g., dosing records, imaging dates, visit dates) were censored at the date of randomization plus 1 day.

Time frame: From Baseline until death from any cause (Median [full range] duration of follow-up in Pertuzumab vs. Placebo arms for Primary Analysis: 24.4 [0-42] months vs. 25.0 [0-41] months; Final Analysis: 46.1 [0-70] months vs. 44.4 [0-68] months)

Population: The intent-to-treat (ITT) population included all randomized participants, regardless of whether study medication was received.

Arm	Measure	Group	Value (MEDIAN)
Pertuzumab + Trastuzumab + Chemotherapy	Overall Survival	Primary Analysis	17.5 Months
Pertuzumab + Trastuzumab + Chemotherapy	Overall Survival	Final Analysis	18.1 Months
Placebo + Trastuzumab + Chemotherapy	Overall Survival	Primary Analysis	14.2 Months
Placebo + Trastuzumab + Chemotherapy	Overall Survival	Final Analysis	14.2 Months

Comparison: Primary Analysis. The null hypothesis is that the survival distribution of OS is the same in the two treatment arms.p-value: 0.056595% CI: [0.71, 1]Stratified Log-Rank

Comparison: Final Analysis95% CI: [0.72, 0.99]

Secondary

Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score

The EORTC QLQ-STO22 is a gastric cancer quality of life questionnaire. There are 22 questions concerning disease, treatment related symptoms, side effects, dysphagia, nutritional aspects, and questions about the emotional problems of gastric cancer (dysphagia, pain, reflux, eating restrictions, anxiety, dry mouth, body image, and hair loss). The questions are grouped into five scales and 4 single items which are related to the symptoms of the disease. Most questions used 4-point scale (1 'Not at all' to 4 'Very much'; 1 question was a yes or no answer). A linear transformation was used to standardize all scores and single-items to a scale of 0 to 100; higher score=better level of functioning or greater degree of symptoms. A positive value means an increase, while a negative values means a decrease, in score at the indicated time-point relative to the score at baseline (Cycle 1, Day 1).

Time frame: Day 1 of each 21-day treatment cycle up to 28 and 60-90 days (post-treatment [PT] monitoring visits 1 and 2, respectively) after Day 1 of last treatment cycle (up to approximately 3.5 years)

Population: Participants in the ITT population (includes all randomized participants, regardless of whether study medication was received) with both a baseline assessment and at least 1 post-treatment assessment are included in the analysis.

Arm	Measure	Group	Value (MEAN)	Dispersion
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at Cycle 17	-2.70 score on a scale	Standard Deviation 32.76
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at Cycle 13	-8.55 score on a scale	Standard Deviation 20.41
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at PT Visit 1	0.19 score on a scale	Standard Deviation 28.7
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at Cycle 14	-8.62 score on a scale	Standard Deviation 19.16
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at Cycle 18	-2.64 score on a scale	Standard Deviation 30.44
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at Cycle 15	-6.85 score on a scale	Standard Deviation 20.92
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at Cycle 14	-14.32 score on a scale	Standard Deviation 26.49
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at Cycle 16	-5.77 score on a scale	Standard Deviation 22.01
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at Cycle 19	-2.81 score on a scale	Standard Deviation 33.57
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at Cycle 17	-5.56 score on a scale	Standard Deviation 21.95
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at Cycle 6	-4.20 score on a scale	Standard Deviation 18.99
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at Cycle 18	-7.27 score on a scale	Standard Deviation 20.4
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at Cycle 20	-3.97 score on a scale	Standard Deviation 30.79
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at Cycle 19	-7.03 score on a scale	Standard Deviation 21.78
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at Cycle 15	-13.42 score on a scale	Standard Deviation 26.64
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at Cycle 20	-4.56 score on a scale	Standard Deviation 21.03
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at Cycle 21	-5.80 score on a scale	Standard Deviation 22.58
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at Cycle 21	1.69 score on a scale	Standard Deviation 30.15
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at Cycle 22	-3.65 score on a scale	Standard Deviation 21.79
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at Cycle 11	-7.69 score on a scale	Standard Deviation 25.46
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at Cycle 23	-3.70 score on a scale	Standard Deviation 22.74
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at Cycle 22	-1.49 score on a scale	Standard Deviation 32.01
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at Cycle 24	-5.00 score on a scale	Standard Deviation 20.77
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at Cycle 7	-4.83 score on a scale	Standard Deviation 20.56
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at Cycle 25	-5.77 score on a scale	Standard Deviation 21.1
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at Cycle 23	-5.82 score on a scale	Standard Deviation 24.35
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at Cycle 26	-6.80 score on a scale	Standard Deviation 21.22
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at Cycle 17	-13.41 score on a scale	Standard Deviation 27.3
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at Cycle 27	-5.62 score on a scale	Standard Deviation 23.48
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at Cycle 24	-0.56 score on a scale	Standard Deviation 31.25
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at Cycle 28	-7.91 score on a scale	Standard Deviation 21.79
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at Cycle 27	-6.98 score on a scale	Standard Deviation 21.28
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at PT Visit 1	1.52 score on a scale	Standard Deviation 24.48
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at Cycle 25	-3.21 score on a scale	Standard Deviation 28.97
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at PT Visit 2	-2.10 score on a scale	Standard Deviation 25.32
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at Cycle 18	-13.53 score on a scale	Standard Deviation 28.05
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Cycle 1 (Baseline)	4.73 score on a scale	Standard Deviation 13.28
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at Cycle 26	-4.76 score on a scale	Standard Deviation 29.66
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at Cycle 2	0.20 score on a scale	Standard Deviation 14.85
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at Cycle 8	-5.96 score on a scale	Standard Deviation 18.8
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at Cycle 3	4.34 score on a scale	Standard Deviation 17.51
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at Cycle 27	0.78 score on a scale	Standard Deviation 24.65
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at Cycle 4	5.40 score on a scale	Standard Deviation 18.46
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at Cycle 19	-14.50 score on a scale	Standard Deviation 27.41
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at Cycle 5	6.12 score on a scale	Standard Deviation 19.38
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at Cycle 28	-4.27 score on a scale	Standard Deviation 26.69
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at PT Visit 2	-1.35 score on a scale	Standard Deviation 30.09
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at Cycle 7	5.72 score on a scale	Standard Deviation 19.91
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at PT Visit 1	2.48 score on a scale	Standard Deviation 31.57
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at Cycle 8	5.00 score on a scale	Standard Deviation 18.96
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at Cycle 20	-15.34 score on a scale	Standard Deviation 29.21
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at Cycle 9	2.38 score on a scale	Standard Deviation 17.43
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at PT Visit 2	2.36 score on a scale	Standard Deviation 35.4
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at Cycle 10	0.64 score on a scale	Standard Deviation 16.88
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at Cycle 9	-6.17 score on a scale	Standard Deviation 18.21
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at Cycle 11	-0.10 score on a scale	Standard Deviation 17.02
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Cycle 1 (Baseline)	21.80 score on a scale	Standard Deviation 25.07
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at Cycle 15	3.08 score on a scale	Standard Deviation 24.36
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at Cycle 21	-16.03 score on a scale	Standard Deviation 28.84
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at Cycle 16	5.51 score on a scale	Standard Deviation 27.9
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at Cycle 17	4.80 score on a scale	Standard Deviation 24.96
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at Cycle 2	7.72 score on a scale	Standard Deviation 28.7
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at Cycle 6	6.93 score on a scale	Standard Deviation 18.87
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at Cycle 18	3.59 score on a scale	Standard Deviation 23.87
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at Cycle 3	6.10 score on a scale	Standard Deviation 28.65
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at Cycle 19	3.13 score on a scale	Standard Deviation 25.17
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at Cycle 22	-13.30 score on a scale	Standard Deviation 30.77
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at Cycle 20	5.56 score on a scale	Standard Deviation 27.78
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at Cycle 4	4.76 score on a scale	Standard Deviation 29.4
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at Cycle 21	6.33 score on a scale	Standard Deviation 27.26
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at Cycle 10	-6.03 score on a scale	Standard Deviation 17.37
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at Cycle 22	9.45 score on a scale	Standard Deviation 30.04
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at Cycle 5	2.47 score on a scale	Standard Deviation 29.67
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at Cycle 23	8.99 score on a scale	Standard Deviation 30.06
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at Cycle 6	2.96 score on a scale	Standard Deviation 30.14
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at Cycle 24	7.78 score on a scale	Standard Deviation 28.37
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at Cycle 23	-17.28 score on a scale	Standard Deviation 30.64
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at Cycle 25	3.21 score on a scale	Standard Deviation 28.97
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at Cycle 7	-1.96 score on a scale	Standard Deviation 28.82
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at Cycle 26	4.08 score on a scale	Standard Deviation 34.45
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at Cycle 26	-2.72 score on a scale	Standard Deviation 23.41
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at Cycle 27	4.65 score on a scale	Standard Deviation 29.62
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at Cycle 8	-2.43 score on a scale	Standard Deviation 28.68
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at Cycle 28	3.42 score on a scale	Standard Deviation 21.35
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at Cycle 24	-16.11 score on a scale	Standard Deviation 30.65
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at PT Visit 1	12.76 score on a scale	Standard Deviation 34.59
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at Cycle 9	-3.70 score on a scale	Standard Deviation 25.7
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at PT Visit 2	8.42 score on a scale	Standard Deviation 31.35
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Cycle 1 (Baseline)	40.10 score on a scale	Standard Deviation 25.85
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at Cycle 10	-6.27 score on a scale	Standard Deviation 25.04
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at Cycle 25	-16.03 score on a scale	Standard Deviation 29.47
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at Cycle 16	-1.47 score on a scale	Standard Deviation 17.47
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at Cycle 14	-1.37 score on a scale	Standard Deviation 17.59
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at Cycle 17	-1.07 score on a scale	Standard Deviation 17.75
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at Cycle 18	-1.68 score on a scale	Standard Deviation 17.58
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at Cycle 12	-8.18 score on a scale	Standard Deviation 24.22
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at Cycle 19	-0.90 score on a scale	Standard Deviation 18.12
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at Cycle 26	-19.73 score on a scale	Standard Deviation 30.28
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at Cycle 20	-0.20 score on a scale	Standard Deviation 19.21
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at Cycle 13	-9.69 score on a scale	Standard Deviation 24.08
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at Cycle 21	-1.07 score on a scale	Standard Deviation 19.43
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at Cycle 14	-8.33 score on a scale	Standard Deviation 24.6
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at Cycle 22	-0.50 score on a scale	Standard Deviation 16.66
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at Cycle 2	-2.58 score on a scale	Standard Deviation 21.72
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at Cycle 23	-0.54 score on a scale	Standard Deviation 16.79
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at Cycle 15	-7.89 score on a scale	Standard Deviation 22.2
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at Cycle 24	-1.39 score on a scale	Standard Deviation 17.44
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at Cycle 27	-21.71 score on a scale	Standard Deviation 29.89
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at Cycle 25	-1.96 score on a scale	Standard Deviation 18.75
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at Cycle 16	-6.32 score on a scale	Standard Deviation 24.44
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at Cycle 26	-1.02 score on a scale	Standard Deviation 19.37
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at Cycle 3	-4.14 score on a scale	Standard Deviation 22.45
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at Cycle 27	-3.10 score on a scale	Standard Deviation 15.96
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at Cycle 17	-7.44 score on a scale	Standard Deviation 23.12
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at Cycle 28	-4.70 score on a scale	Standard Deviation 20.57
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at Cycle 28	-22.51 score on a scale	Standard Deviation 29.34
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at PT Visit 1	4.98 score on a scale	Standard Deviation 19.73
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at Cycle 18	-5.56 score on a scale	Standard Deviation 24.86
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at PT Visit 2	15.82 score on a scale	Standard Deviation 25.35
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Cycle 1 (Baseline)	16.29 score on a scale	Standard Deviation 21.46
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Cycle 1 (Baseline)	26.48 score on a scale	Standard Deviation 21.34
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at Cycle 19	-5.90 score on a scale	Standard Deviation 24.18
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at Cycle 2	-4.63 score on a scale	Standard Deviation 20.3
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at PT Visit 1	-0.73 score on a scale	Standard Deviation 25.18
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at Cycle 3	-6.96 score on a scale	Standard Deviation 20.37
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at Cycle 20	-6.35 score on a scale	Standard Deviation 26.62
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at Cycle 4	-6.45 score on a scale	Standard Deviation 21.47
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at Cycle 4	-4.52 score on a scale	Standard Deviation 23.01
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at Cycle 5	-7.28 score on a scale	Standard Deviation 20.95
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at Cycle 21	-7.17 score on a scale	Standard Deviation 24.27
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at Cycle 6	-7.24 score on a scale	Standard Deviation 20.84
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at PT Visit 2	-4.04 score on a scale	Standard Deviation 28.24
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at Cycle 7	-9.52 score on a scale	Standard Deviation 21.18
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at Cycle 22	-3.98 score on a scale	Standard Deviation 26.29
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at Cycle 8	-10.53 score on a scale	Standard Deviation 21.62
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at Cycle 15	-0.39 score on a scale	Standard Deviation 15.65
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at Cycle 9	-10.08 score on a scale	Standard Deviation 19.6
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at Cycle 23	-7.94 score on a scale	Standard Deviation 23.73
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at Cycle 10	-10.63 score on a scale	Standard Deviation 19.23
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Cycle 1 (Baseline)	23.53 score on a scale	Standard Deviation 28.4
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at Cycle 11	-11.65 score on a scale	Standard Deviation 19.35
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at Cycle 24	-6.67 score on a scale	Standard Deviation 25.15
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at Cycle 12	-11.76 score on a scale	Standard Deviation 19.87
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at Cycle 11	-6.25 score on a scale	Standard Deviation 17.09
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at Cycle 13	-11.92 score on a scale	Standard Deviation 18.93
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at Cycle 5	-4.10 score on a scale	Standard Deviation 22.94
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at Cycle 14	-11.66 score on a scale	Standard Deviation 19.51
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at Cycle 12	-7.06 score on a scale	Standard Deviation 17.65
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at Cycle 15	-11.15 score on a scale	Standard Deviation 18.16
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at Cycle 2	1.33 score on a scale	Standard Deviation 28.19
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at Cycle 16	-8.72 score on a scale	Standard Deviation 18.02
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at Cycle 13	-6.93 score on a scale	Standard Deviation 18.71
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at Cycle 17	-8.88 score on a scale	Standard Deviation 18.17
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at Cycle 28	-8.55 score on a scale	Standard Deviation 21.24
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at Cycle 18	-8.31 score on a scale	Standard Deviation 18.33
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at Cycle 14	-8.01 score on a scale	Standard Deviation 18.53
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at Cycle 19	-6.63 score on a scale	Standard Deviation 17.25
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at Cycle 3	1.48 score on a scale	Standard Deviation 29.06
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at Cycle 20	-5.72 score on a scale	Standard Deviation 19.98
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at Cycle 15	-6.45 score on a scale	Standard Deviation 17.38
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at Cycle 21	-8.19 score on a scale	Standard Deviation 18.27
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at Cycle 6	-4.54 score on a scale	Standard Deviation 23.97
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at Cycle 22	-9.08 score on a scale	Standard Deviation 18.1
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at Cycle 16	-4.41 score on a scale	Standard Deviation 18.29
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at Cycle 23	-9.66 score on a scale	Standard Deviation 20.75
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at Cycle 4	4.20 score on a scale	Standard Deviation 28.51
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at Cycle 24	-9.86 score on a scale	Standard Deviation 21.56
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at Cycle 17	-5.36 score on a scale	Standard Deviation 16.87
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at Cycle 25	-10.58 score on a scale	Standard Deviation 19.88
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at Cycle 2	-2.27 score on a scale	Standard Deviation 17.64
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at Cycle 26	-9.01 score on a scale	Standard Deviation 17.99
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at Cycle 18	-4.90 score on a scale	Standard Deviation 16.44
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at Cycle 27	-12.02 score on a scale	Standard Deviation 17.28
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at Cycle 5	2.86 score on a scale	Standard Deviation 30.91
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at Cycle 28	-11.54 score on a scale	Standard Deviation 18.2
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at Cycle 19	-4.40 score on a scale	Standard Deviation 17.1
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at PT Visit 1	-1.70 score on a scale	Standard Deviation 23.07
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at Cycle 7	-6.40 score on a scale	Standard Deviation 24
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at PT Visit 2	-7.49 score on a scale	Standard Deviation 24.09
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at Cycle 20	-2.51 score on a scale	Standard Deviation 16.21
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Cycle 1 (Baseline)	16.68 score on a scale	Standard Deviation 19.03
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at Cycle 12	0.21 score on a scale	Standard Deviation 19.7
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at Cycle 6	0.75 score on a scale	Standard Deviation 30.11
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at Cycle 2	-0.13 score on a scale	Standard Deviation 16.33
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at Cycle 21	-3.80 score on a scale	Standard Deviation 19.24
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at Cycle 3	-0.52 score on a scale	Standard Deviation 18.95
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at Cycle 25	-8.33 score on a scale	Standard Deviation 22.75
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at Cycle 4	-0.98 score on a scale	Standard Deviation 19.18
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at Cycle 22	-3.65 score on a scale	Standard Deviation 20.41
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at Cycle 5	-1.92 score on a scale	Standard Deviation 18.98
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at Cycle 7	-0.56 score on a scale	Standard Deviation 28.94
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at Cycle 6	-2.90 score on a scale	Standard Deviation 20.42
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at Cycle 23	-4.23 score on a scale	Standard Deviation 18.87
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at Cycle 7	-4.18 score on a scale	Standard Deviation 18.36
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at Cycle 8	-9.00 score on a scale	Standard Deviation 23.17
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at Cycle 8	-4.96 score on a scale	Standard Deviation 19.39
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at Cycle 24	-5.00 score on a scale	Standard Deviation 18.35
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at Cycle 9	-5.02 score on a scale	Standard Deviation 18.97
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at Cycle 8	-1.74 score on a scale	Standard Deviation 29.83
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at Cycle 10	-6.12 score on a scale	Standard Deviation 17.81
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at Cycle 25	-5.98 score on a scale	Standard Deviation 19.61
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at Cycle 11	-6.44 score on a scale	Standard Deviation 18.74
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at Cycle 3	-3.39 score on a scale	Standard Deviation 18.57
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at Cycle 12	-4.82 score on a scale	Standard Deviation 18
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at Cycle 26	-5.67 score on a scale	Standard Deviation 20.43
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at Cycle 13	-6.42 score on a scale	Standard Deviation 17.09
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at Cycle 9	-3.58 score on a scale	Standard Deviation 28.74
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at Cycle 14	-5.39 score on a scale	Standard Deviation 18.24
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at Cycle 27	-5.68 score on a scale	Standard Deviation 20.91
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at Cycle 15	-5.00 score on a scale	Standard Deviation 16.66
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at Cycle 9	-10.09 score on a scale	Standard Deviation 23.3
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at Cycle 16	-3.07 score on a scale	Standard Deviation 18.39
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at Cycle 28	-8.26 score on a scale	Standard Deviation 19.86
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at Cycle 17	-3.35 score on a scale	Standard Deviation 18.38
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at Cycle 10	-5.07 score on a scale	Standard Deviation 30.15
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at Cycle 18	-2.94 score on a scale	Standard Deviation 18.36
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at PT Visit 1	0.44 score on a scale	Standard Deviation 24.15
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at Cycle 19	-2.43 score on a scale	Standard Deviation 16.38
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at Cycle 10	-11.17 score on a scale	Standard Deviation 25.05
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at Cycle 20	-1.85 score on a scale	Standard Deviation 18.32
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at PT Visit 2	-2.81 score on a scale	Standard Deviation 24.4
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at Cycle 21	-1.83 score on a scale	Standard Deviation 18.44
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at Cycle 11	-4.62 score on a scale	Standard Deviation 30.24
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at Cycle 22	-3.81 score on a scale	Standard Deviation 19.3
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Cycle 1 (Baseline)	23.26 score on a scale	Standard Deviation 21.78
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at Cycle 23	-5.11 score on a scale	Standard Deviation 17.03
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at Cycle 4	-2.94 score on a scale	Standard Deviation 18.93
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at Cycle 24	-4.07 score on a scale	Standard Deviation 19.3
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at Cycle 2	-1.41 score on a scale	Standard Deviation 19.36
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at Cycle 25	-5.56 score on a scale	Standard Deviation 18.86
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at Cycle 12	-5.31 score on a scale	Standard Deviation 31.92
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at Cycle 26	-4.99 score on a scale	Standard Deviation 20.67
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at Cycle 3	-1.04 score on a scale	Standard Deviation 21.09
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at Cycle 27	-7.75 score on a scale	Standard Deviation 20.51
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at Cycle 11	-10.78 score on a scale	Standard Deviation 23.47
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at Cycle 28	-7.12 score on a scale	Standard Deviation 18.64
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at Cycle 4	-2.24 score on a scale	Standard Deviation 20.81
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at PT Visit 1	0.88 score on a scale	Standard Deviation 20.01
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at Cycle 13	-4.73 score on a scale	Standard Deviation 30.23
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at PT Visit 2	0.56 score on a scale	Standard Deviation 18.67
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at Cycle 5	-1.39 score on a scale	Standard Deviation 22.1
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Cycle 1 (Baseline)	13.79 score on a scale	Standard Deviation 23.99
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at Cycle 16	-12.75 score on a scale	Standard Deviation 26.87
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at Cycle 2	12.09 score on a scale	Standard Deviation 28.78
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at Cycle 6	-1.35 score on a scale	Standard Deviation 22.77
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at Cycle 3	16.72 score on a scale	Standard Deviation 32.11
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at Cycle 14	-5.43 score on a scale	Standard Deviation 29.7
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at Cycle 4	18.43 score on a scale	Standard Deviation 34.7
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at Cycle 7	-2.45 score on a scale	Standard Deviation 22.68
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at Cycle 5	17.61 score on a scale	Standard Deviation 32.93
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at Cycle 12	-12.62 score on a scale	Standard Deviation 26.24
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at Cycle 6	17.97 score on a scale	Standard Deviation 31.2
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at Cycle 8	-4.29 score on a scale	Standard Deviation 22.7
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at Cycle 7	16.25 score on a scale	Standard Deviation 33.51
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at Cycle 15	-3.08 score on a scale	Standard Deviation 30.63
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at Cycle 8	11.64 score on a scale	Standard Deviation 29.81
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at Cycle 9	-6.99 score on a scale	Standard Deviation 21.16
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at Cycle 9	9.22 score on a scale	Standard Deviation 28.25
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at Cycle 5	-3.22 score on a scale	Standard Deviation 19.92
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at Cycle 10	7.93 score on a scale	Standard Deviation 26.41
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at Cycle 10	-7.06 score on a scale	Standard Deviation 21.32
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at Cycle 11	4.96 score on a scale	Standard Deviation 26.72
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at Cycle 16	-1.74 score on a scale	Standard Deviation 32.99
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at Cycle 12	5.27 score on a scale	Standard Deviation 24.82
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at Cycle 11	-8.22 score on a scale	Standard Deviation 21.25
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at Cycle 13	4.08 score on a scale	Standard Deviation 25.53
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at Cycle 13	-13.32 score on a scale	Standard Deviation 25.93
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at Cycle 14	0.49 score on a scale	Standard Deviation 25.66
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at Cycle 13	0.36 score on a scale	Standard Deviation 18.91
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at Cycle 12	-7.74 score on a scale	Standard Deviation 21.16
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at Cycle 13	2.29 score on a scale	Standard Deviation 15.46
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at Cycle 25	-9.52 score on a scale	Standard Deviation 28.66
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at Cycle 26	-7.53 score on a scale	Standard Deviation 26.82
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at Cycle 27	-7.14 score on a scale	Standard Deviation 27.75
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at Cycle 28	-8.00 score on a scale	Standard Deviation 22.11
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at PT Visit 1	2.38 score on a scale	Standard Deviation 31.58
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at PT Visit 2	1.89 score on a scale	Standard Deviation 25.95
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Cycle 1 (Baseline)	14.15 score on a scale	Standard Deviation 18.93
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at Cycle 2	-4.11 score on a scale	Standard Deviation 21.19
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at Cycle 5	2.57 score on a scale	Standard Deviation 28.68
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at Cycle 13	-8.48 score on a scale	Standard Deviation 26.5
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at Cycle 20	-4.44 score on a scale	Standard Deviation 16.72
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at Cycle 12	1.96 score on a scale	Standard Deviation 15.72
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at Cycle 14	1.83 score on a scale	Standard Deviation 15.15
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at Cycle 17	0.23 score on a scale	Standard Deviation 12.57
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at Cycle 2	-0.53 score on a scale	Standard Deviation 19.32
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at Cycle 3	-2.15 score on a scale	Standard Deviation 19.67
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at Cycle 4	-1.08 score on a scale	Standard Deviation 18.79
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at Cycle 5	-1.83 score on a scale	Standard Deviation 18.99
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at Cycle 6	-2.25 score on a scale	Standard Deviation 18.7
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at Cycle 7	-1.97 score on a scale	Standard Deviation 19.94
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at Cycle 8	-3.29 score on a scale	Standard Deviation 18.48
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at Cycle 9	-3.86 score on a scale	Standard Deviation 18.49
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at Cycle 10	-4.61 score on a scale	Standard Deviation 16.87
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Cycle 1 (Baseline)	40.48 score on a scale	Standard Deviation 25.32
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at Cycle 3	-3.87 score on a scale	Standard Deviation 23.19
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at Cycle 4	-7.25 score on a scale	Standard Deviation 23.16
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at Cycle 5	-7.39 score on a scale	Standard Deviation 24.36
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at Cycle 6	-8.42 score on a scale	Standard Deviation 25.21
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at Cycle 7	-10.40 score on a scale	Standard Deviation 24.37
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at Cycle 8	-11.92 score on a scale	Standard Deviation 24.5
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at Cycle 9	-11.43 score on a scale	Standard Deviation 23.24
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at Cycle 10	-12.64 score on a scale	Standard Deviation 22.09
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at Cycle 11	-12.09 score on a scale	Standard Deviation 21.84
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at Cycle 12	-13.16 score on a scale	Standard Deviation 23.11
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at Cycle 13	-13.33 score on a scale	Standard Deviation 22.47
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at Cycle 14	-12.43 score on a scale	Standard Deviation 23.59
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at Cycle 15	-10.65 score on a scale	Standard Deviation 25.74
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at Cycle 16	-12.57 score on a scale	Standard Deviation 23.89
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at Cycle 17	-12.79 score on a scale	Standard Deviation 21.01
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at Cycle 18	-12.38 score on a scale	Standard Deviation 22.9
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at Cycle 19	-12.48 score on a scale	Standard Deviation 20.08
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at Cycle 20	-12.37 score on a scale	Standard Deviation 23.73
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at Cycle 21	-14.47 score on a scale	Standard Deviation 25
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at Cycle 22	-15.46 score on a scale	Standard Deviation 23.83
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at Cycle 23	-14.47 score on a scale	Standard Deviation 29.55
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at Cycle 24	-17.09 score on a scale	Standard Deviation 23.76
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at Cycle 25	-17.78 score on a scale	Standard Deviation 23.68
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at Cycle 26	-13.26 score on a scale	Standard Deviation 22.11
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at Cycle 27	-12.70 score on a scale	Standard Deviation 20.67
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at Cycle 28	-12.89 score on a scale	Standard Deviation 22.38
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at PT Visit 1	-4.73 score on a scale	Standard Deviation 27.21
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Anxiety: Change at PT Visit 2	-3.98 score on a scale	Standard Deviation 25.02
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Cycle 1 (Baseline)	23.68 score on a scale	Standard Deviation 27.47
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at Cycle 2	1.20 score on a scale	Standard Deviation 26.44
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at Cycle 3	3.88 score on a scale	Standard Deviation 28.03
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at Cycle 4	1.15 score on a scale	Standard Deviation 27.19
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at Cycle 5	1.06 score on a scale	Standard Deviation 25.74
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at Cycle 6	2.78 score on a scale	Standard Deviation 28.48
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at Cycle 7	0.29 score on a scale	Standard Deviation 25.53
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at Cycle 8	0.00 score on a scale	Standard Deviation 26.3
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at Cycle 9	-0.69 score on a scale	Standard Deviation 24.52
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at Cycle 10	-3.25 score on a scale	Standard Deviation 24.55
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at Cycle 11	-1.53 score on a scale	Standard Deviation 25.46
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at Cycle 12	-2.66 score on a scale	Standard Deviation 27.04
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at Cycle 13	-2.73 score on a scale	Standard Deviation 25.99
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at Cycle 14	-4.62 score on a scale	Standard Deviation 24.05
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at Cycle 15	-2.43 score on a scale	Standard Deviation 27.03
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at Cycle 16	-1.19 score on a scale	Standard Deviation 26.1
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at Cycle 17	-2.28 score on a scale	Standard Deviation 21.75
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at Cycle 18	-5.71 score on a scale	Standard Deviation 23.38
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at Cycle 19	-5.21 score on a scale	Standard Deviation 20.76
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at Cycle 20	-5.38 score on a scale	Standard Deviation 22.74
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at Cycle 21	-8.18 score on a scale	Standard Deviation 26.07
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at Cycle 22	-10.87 score on a scale	Standard Deviation 22.28
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at Cycle 23	-8.53 score on a scale	Standard Deviation 29.18
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at Cycle 24	-11.11 score on a scale	Standard Deviation 23.36
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at Cycle 25	-11.43 score on a scale	Standard Deviation 24.18
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at Cycle 26	-6.45 score on a scale	Standard Deviation 18.09
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at Cycle 27	-7.14 score on a scale	Standard Deviation 21
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at Cycle 28	-4.00 score on a scale	Standard Deviation 24.19
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at PT Visit 1	3.42 score on a scale	Standard Deviation 29.31
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Body Image: Change at PT Visit 2	6.35 score on a scale	Standard Deviation 27.38
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Cycle 1 (Baseline)	23.32 score on a scale	Standard Deviation 26.79
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at Cycle 2	3.00 score on a scale	Standard Deviation 25.43
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at Cycle 3	4.87 score on a scale	Standard Deviation 27.33
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at Cycle 4	2.66 score on a scale	Standard Deviation 31.06
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at Cycle 6	1.19 score on a scale	Standard Deviation 27.65
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at Cycle 7	0.44 score on a scale	Standard Deviation 28.54
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at Cycle 8	-2.66 score on a scale	Standard Deviation 26.27
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at Cycle 9	-4.32 score on a scale	Standard Deviation 24.74
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at Cycle 10	-3.46 score on a scale	Standard Deviation 23.53
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at Cycle 11	-1.96 score on a scale	Standard Deviation 26.56
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at Cycle 12	-4.35 score on a scale	Standard Deviation 26.36
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at Cycle 14	-3.63 score on a scale	Standard Deviation 29.78
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at Cycle 15	-7.29 score on a scale	Standard Deviation 26.58
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at Cycle 16	-8.33 score on a scale	Standard Deviation 27.8
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at Cycle 17	-3.20 score on a scale	Standard Deviation 24.32
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at Cycle 18	-8.10 score on a scale	Standard Deviation 28.62
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at Cycle 19	-7.69 score on a scale	Standard Deviation 25.53
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at Cycle 20	-9.68 score on a scale	Standard Deviation 27.25
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at Cycle 21	-9.43 score on a scale	Standard Deviation 20.02
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at Cycle 22	-8.70 score on a scale	Standard Deviation 23.76
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at Cycle 23	-3.88 score on a scale	Standard Deviation 25.42
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at Cycle 11	-2.83 score on a scale	Standard Deviation 17.03
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at Cycle 12	-4.19 score on a scale	Standard Deviation 15.84
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at Cycle 13	-3.54 score on a scale	Standard Deviation 17.61
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at Cycle 14	-4.95 score on a scale	Standard Deviation 18.22
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at Cycle 15	-2.14 score on a scale	Standard Deviation 18.69
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at Cycle 16	-3.70 score on a scale	Standard Deviation 21.08
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at Cycle 17	-3.20 score on a scale	Standard Deviation 14.99
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at Cycle 18	-3.33 score on a scale	Standard Deviation 19.78
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at Cycle 19	-3.59 score on a scale	Standard Deviation 14.31
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at Cycle 20	-3.76 score on a scale	Standard Deviation 15.83
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at Cycle 21	-2.10 score on a scale	Standard Deviation 17.84
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at Cycle 22	-4.83 score on a scale	Standard Deviation 15.65
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at Cycle 23	-3.88 score on a scale	Standard Deviation 17.63
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at Cycle 24	-3.70 score on a scale	Standard Deviation 13.08
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at Cycle 25	-2.22 score on a scale	Standard Deviation 16.79
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at Cycle 26	-2.87 score on a scale	Standard Deviation 16.22
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at Cycle 27	-4.37 score on a scale	Standard Deviation 12.22
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at Cycle 28	-3.56 score on a scale	Standard Deviation 11.44
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at PT Visit 1	2.83 score on a scale	Standard Deviation 22.63
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dysphagia: Change at PT Visit 2	3.25 score on a scale	Standard Deviation 19.81
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Cycle 1 (Baseline)	22.33 score on a scale	Standard Deviation 20.22
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at Cycle 2	-1.54 score on a scale	Standard Deviation 19.62
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at Cycle 3	-2.20 score on a scale	Standard Deviation 20.94
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at Cycle 4	-1.39 score on a scale	Standard Deviation 23.36
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at Cycle 5	-0.09 score on a scale	Standard Deviation 23.31
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at Cycle 6	-3.32 score on a scale	Standard Deviation 23.14
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at Cycle 7	-2.67 score on a scale	Standard Deviation 21.66
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at Cycle 8	-5.56 score on a scale	Standard Deviation 19.87
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at Cycle 9	-6.48 score on a scale	Standard Deviation 19.69
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at Cycle 10	-5.89 score on a scale	Standard Deviation 19.3
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at Cycle 11	-5.05 score on a scale	Standard Deviation 19.98
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at Cycle 12	-6.34 score on a scale	Standard Deviation 19.87
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at Cycle 13	-8.41 score on a scale	Standard Deviation 19.57
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at Cycle 14	-8.58 score on a scale	Standard Deviation 21.16
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at Cycle 15	-5.56 score on a scale	Standard Deviation 21.21
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at Cycle 16	-6.94 score on a scale	Standard Deviation 20.36
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at Cycle 17	-7.42 score on a scale	Standard Deviation 17.76
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at Cycle 18	-6.90 score on a scale	Standard Deviation 21.14
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at Cycle 19	-5.38 score on a scale	Standard Deviation 18.07
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at Cycle 21	-5.03 score on a scale	Standard Deviation 19.97
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at Cycle 22	-6.16 score on a scale	Standard Deviation 16.8
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at Cycle 23	-5.23 score on a scale	Standard Deviation 20.25
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at Cycle 24	-7.91 score on a scale	Standard Deviation 15.76
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at Cycle 25	-5.95 score on a scale	Standard Deviation 16.61
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at Cycle 26	-2.42 score on a scale	Standard Deviation 22.89
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at Cycle 27	-3.87 score on a scale	Standard Deviation 10.26
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at Cycle 28	-5.00 score on a scale	Standard Deviation 11.02
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at PT Visit 1	0.94 score on a scale	Standard Deviation 24.7
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Eating Restrictions: Change at PT Visit 2	0.94 score on a scale	Standard Deviation 21.46
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Cycle 1 (Baseline)	4.04 score on a scale	Standard Deviation 13.2
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at Cycle 2	1.27 score on a scale	Standard Deviation 16.59
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at Cycle 3	4.52 score on a scale	Standard Deviation 18.71
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at Cycle 4	6.53 score on a scale	Standard Deviation 20.99
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at Cycle 5	7.18 score on a scale	Standard Deviation 19.49
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at Cycle 6	10.07 score on a scale	Standard Deviation 22.94
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at Cycle 7	9.26 score on a scale	Standard Deviation 22.92
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at Cycle 8	7.38 score on a scale	Standard Deviation 23.05
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at Cycle 9	6.46 score on a scale	Standard Deviation 21.06
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at Cycle 10	4.22 score on a scale	Standard Deviation 19.51
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at Cycle 14	-5.28 score on a scale	Standard Deviation 24.37
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at Cycle 15	-1.04 score on a scale	Standard Deviation 26.25
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at Cycle 16	-3.57 score on a scale	Standard Deviation 20.71
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at Cycle 17	-3.65 score on a scale	Standard Deviation 23.28
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at Cycle 18	-4.29 score on a scale	Standard Deviation 23.34
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at Cycle 19	-4.62 score on a scale	Standard Deviation 15.45
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at Cycle 20	-3.76 score on a scale	Standard Deviation 18.21
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at Cycle 21	-5.03 score on a scale	Standard Deviation 17.78
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at Cycle 22	-4.35 score on a scale	Standard Deviation 16.64
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at Cycle 23	0.00 score on a scale	Standard Deviation 23
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at Cycle 24	-5.13 score on a scale	Standard Deviation 19.55
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at Cycle 25	-4.76 score on a scale	Standard Deviation 18.33
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at Cycle 26	-3.23 score on a scale	Standard Deviation 21.7
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at Cycle 27	-3.57 score on a scale	Standard Deviation 20.96
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at Cycle 28	-6.67 score on a scale	Standard Deviation 25.46
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at PT Visit 1	9.06 score on a scale	Standard Deviation 33.56
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at PT Visit 2	6.67 score on a scale	Standard Deviation 28.64
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at Cycle 11	2.54 score on a scale	Standard Deviation 17.51
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at Cycle 15	1.58 score on a scale	Standard Deviation 12.65
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at Cycle 16	1.42 score on a scale	Standard Deviation 13.91
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at Cycle 18	-0.71 score on a scale	Standard Deviation 13.14
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at Cycle 19	0.51 score on a scale	Standard Deviation 14.12
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at Cycle 20	-1.61 score on a scale	Standard Deviation 12.7
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at Cycle 21	-1.57 score on a scale	Standard Deviation 8.81
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at Cycle 22	-3.26 score on a scale	Standard Deviation 11.98
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at Cycle 23	-1.19 score on a scale	Standard Deviation 11.28
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at Cycle 24	1.71 score on a scale	Standard Deviation 16.13
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at Cycle 25	-0.95 score on a scale	Standard Deviation 9.85
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at Cycle 26	-0.54 score on a scale	Standard Deviation 10.08
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at Cycle 27	-0.60 score on a scale	Standard Deviation 10.62
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at Cycle 28	-1.33 score on a scale	Standard Deviation 10.67
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at PT Visit 1	4.51 score on a scale	Standard Deviation 20.39
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Hair Loss: Change at PT Visit 2	22.22 score on a scale	Standard Deviation 30.81
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Cycle 1 (Baseline)	26.47 score on a scale	Standard Deviation 20.7
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at Cycle 2	-5.86 score on a scale	Standard Deviation 19.15
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at Cycle 3	-5.86 score on a scale	Standard Deviation 20.68
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at Cycle 4	-7.48 score on a scale	Standard Deviation 21.23
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at Cycle 5	-6.89 score on a scale	Standard Deviation 22.1
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at Cycle 6	-7.22 score on a scale	Standard Deviation 21.62
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at Cycle 7	-6.62 score on a scale	Standard Deviation 21.63
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at Cycle 8	-8.16 score on a scale	Standard Deviation 20.11
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at Cycle 9	-8.98 score on a scale	Standard Deviation 20.29
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at Cycle 10	-8.59 score on a scale	Standard Deviation 20.38
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at Cycle 11	-8.01 score on a scale	Standard Deviation 18.97
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at Cycle 12	-7.19 score on a scale	Standard Deviation 19.11
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at Cycle 13	-9.24 score on a scale	Standard Deviation 19.79
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at Cycle 14	-9.82 score on a scale	Standard Deviation 19.91
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at Cycle 15	-8.51 score on a scale	Standard Deviation 20.94
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at Cycle 16	-10.52 score on a scale	Standard Deviation 21.3
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at Cycle 17	-9.93 score on a scale	Standard Deviation 17.27
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at Cycle 18	-11.19 score on a scale	Standard Deviation 18.16
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at Cycle 19	-10.38 score on a scale	Standard Deviation 14.51
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at Cycle 20	-10.35 score on a scale	Standard Deviation 16.65
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at Cycle 21	-7.55 score on a scale	Standard Deviation 16.77
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at Cycle 22	-9.42 score on a scale	Standard Deviation 16.72
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at Cycle 23	-8.53 score on a scale	Standard Deviation 19.96
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at Cycle 24	-8.76 score on a scale	Standard Deviation 15.53
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at Cycle 25	-8.10 score on a scale	Standard Deviation 18.69
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at Cycle 26	-9.41 score on a scale	Standard Deviation 17.58
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at Cycle 27	-9.23 score on a scale	Standard Deviation 14.58
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at Cycle 28	-7.33 score on a scale	Standard Deviation 13.46
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at PT Visit 1	-2.99 score on a scale	Standard Deviation 23.86
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Pain: Change at PT Visit 2	-0.03 score on a scale	Standard Deviation 22.04
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Cycle 1 (Baseline)	17.34 score on a scale	Standard Deviation 18.31
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at Cycle 2	-1.99 score on a scale	Standard Deviation 18.03
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at Cycle 3	-2.28 score on a scale	Standard Deviation 19.53
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at Cycle 4	-1.90 score on a scale	Standard Deviation 19.93
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at Cycle 5	-1.72 score on a scale	Standard Deviation 20.1
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at Cycle 6	-3.59 score on a scale	Standard Deviation 19.04
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at Cycle 7	-3.20 score on a scale	Standard Deviation 20.21
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at Cycle 8	-5.74 score on a scale	Standard Deviation 19.53
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at Cycle 9	-5.18 score on a scale	Standard Deviation 19.81
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at Cycle 10	-6.48 score on a scale	Standard Deviation 18.55
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at Cycle 11	-6.03 score on a scale	Standard Deviation 18.07
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at Cycle 12	-7.49 score on a scale	Standard Deviation 16.99
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at Cycle 13	-6.77 score on a scale	Standard Deviation 18.19
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at Cycle 14	-7.37 score on a scale	Standard Deviation 17.45
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at Cycle 15	-4.98 score on a scale	Standard Deviation 18.72
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at Cycle 16	-4.89 score on a scale	Standard Deviation 22.31
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at Cycle 17	-4.57 score on a scale	Standard Deviation 20.44
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at Cycle 18	-6.51 score on a scale	Standard Deviation 20.33
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at Cycle 19	-6.15 score on a scale	Standard Deviation 18.43
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at Cycle 20	-5.38 score on a scale	Standard Deviation 18.63
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at Cycle 21	-4.19 score on a scale	Standard Deviation 17.73
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at Cycle 22	-7.00 score on a scale	Standard Deviation 19.65
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at Cycle 23	-6.98 score on a scale	Standard Deviation 19.7
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at Cycle 24	-7.98 score on a scale	Standard Deviation 18.19
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at Cycle 25	-5.71 score on a scale	Standard Deviation 16.69
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at Cycle 26	-4.30 score on a scale	Standard Deviation 21.98
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at Cycle 27	-6.75 score on a scale	Standard Deviation 16.1
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at Cycle 28	-4.44 score on a scale	Standard Deviation 11.56
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at PT Visit 1	-0.45 score on a scale	Standard Deviation 22.92
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Reflux Symptoms: Change at PT Visit 2	-1.47 score on a scale	Standard Deviation 22.28
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Cycle 1 (Baseline)	16.22 score on a scale	Standard Deviation 25.49
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at Cycle 2	6.61 score on a scale	Standard Deviation 26.94
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at Cycle 3	9.99 score on a scale	Standard Deviation 30.16
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at Cycle 4	11.07 score on a scale	Standard Deviation 31.93
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at Cycle 5	11.85 score on a scale	Standard Deviation 30.25
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at Cycle 6	11.82 score on a scale	Standard Deviation 32.21
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at Cycle 7	9.19 score on a scale	Standard Deviation 31.09
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at Cycle 8	3.29 score on a scale	Standard Deviation 28.13
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at Cycle 9	1.73 score on a scale	Standard Deviation 26.3
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at Cycle 10	1.63 score on a scale	Standard Deviation 28.79
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at Cycle 11	2.61 score on a scale	Standard Deviation 26.91
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at Cycle 12	0.24 score on a scale	Standard Deviation 24.66
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Taste: Change at Cycle 13	-0.91 score on a scale	Standard Deviation 25.33
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score	Dry Mouth: Change at Cycle 24	-9.40 score on a scale	Standard Deviation 28.56

Secondary

Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score

The EORTC QLQ-C30 included global health status, functional scales (physical, role, emotional, cognitive, and social), symptom scales (fatigue, nausea/vomiting, and pain) and single items (dyspnoea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Most questions used a 4-point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale \[1 'very poor' to 7 'Excellent'\]). Scores were averaged and transformed to 0 - 100 scale, whereby higher scores indicate greater functioning, greater quality of life, or a greater degree of symptoms, with changes of 5 - 10 points considered to be a minimally important difference to participants. A positive value means an increase, while a negative value means a decrease, in score at the indicated time-point relative to the score at baseline (Cycle 1, Day 1).

Arm	Measure	Group	Value (MEAN)	Dispersion
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at Cycle 15	-2.84 score on a scale	Standard Deviation 21.26
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at PT Visit 1	-5.48 score on a scale	Standard Deviation 23.16
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at Cycle 7	0.00 score on a scale	Standard Deviation 21.94
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at PT Visit 2	-2.64 score on a scale	Standard Deviation 23.33
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at Cycle 9	-6.67 score on a scale	Standard Deviation 31.92
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Cycle 1 (Baseline)	31.96 score on a scale	Standard Deviation 23.46
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at Cycle 19	3.82 score on a scale	Standard Deviation 19.86
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at Cycle 2	3.13 score on a scale	Standard Deviation 19.8
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at Cycle 10	-8.06 score on a scale	Standard Deviation 32.52
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at Cycle 3	1.41 score on a scale	Standard Deviation 22.65
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at Cycle 26	-4.99 score on a scale	Standard Deviation 24.85
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at Cycle 4	2.77 score on a scale	Standard Deviation 23.14
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at Cycle 11	-9.36 score on a scale	Standard Deviation 33.19
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at Cycle 5	3.87 score on a scale	Standard Deviation 25.75
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at Cycle 27	-6.98 score on a scale	Standard Deviation 23.76
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at Cycle 6	4.37 score on a scale	Standard Deviation 25.64
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at Cycle 12	-9.22 score on a scale	Standard Deviation 33.73
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at Cycle 7	2.36 score on a scale	Standard Deviation 26.79
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at Cycle 8	-0.19 score on a scale	Standard Deviation 25
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at Cycle 17	-1.82 score on a scale	Standard Deviation 20.61
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at Cycle 9	-2.38 score on a scale	Standard Deviation 22.69
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at Cycle 9	-1.12 score on a scale	Standard Deviation 20.51
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at Cycle 10	-3.41 score on a scale	Standard Deviation 24.69
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at Cycle 13	-10.17 score on a scale	Standard Deviation 31.1
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at Cycle 11	-4.35 score on a scale	Standard Deviation 22.66
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at Cycle 28	-6.39 score on a scale	Standard Deviation 18.98
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at Cycle 12	-3.14 score on a scale	Standard Deviation 24.56
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at Cycle 18	-0.98 score on a scale	Standard Deviation 20.15
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at Cycle 13	-4.57 score on a scale	Standard Deviation 23.31
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at Cycle 14	-12.10 score on a scale	Standard Deviation 31.96
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at Cycle 14	-6.75 score on a scale	Standard Deviation 24.32
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at Cycle 12	-3.35 score on a scale	Standard Deviation 20
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at Cycle 15	-5.47 score on a scale	Standard Deviation 24.68
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at Cycle 15	-8.21 score on a scale	Standard Deviation 32.96
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at Cycle 16	-3.54 score on a scale	Standard Deviation 24.81
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at PT Visit 2	7.70 score on a scale	Standard Deviation 27.65
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at Cycle 17	-4.27 score on a scale	Standard Deviation 25.5
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at Cycle 16	-6.03 score on a scale	Standard Deviation 33.07
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at Cycle 18	-4.14 score on a scale	Standard Deviation 24.42
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at Cycle 10	-0.54 score on a scale	Standard Deviation 21.56
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at Cycle 19	-5.32 score on a scale	Standard Deviation 27.83
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at Cycle 20	-1.19 score on a scale	Standard Deviation 20.98
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at Cycle 20	-5.56 score on a scale	Standard Deviation 26.64
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at Cycle 2	-0.90 score on a scale	Standard Deviation 26.85
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at Cycle 21	-3.94 score on a scale	Standard Deviation 25.97
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at Cycle 17	-6.55 score on a scale	Standard Deviation 29.29
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at Cycle 22	-1.49 score on a scale	Standard Deviation 25.58
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at Cycle 11	-2.16 score on a scale	Standard Deviation 19.58
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at Cycle 23	-5.82 score on a scale	Standard Deviation 25.23
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at Cycle 18	-4.90 score on a scale	Standard Deviation 31.25
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at Cycle 24	-1.67 score on a scale	Standard Deviation 27.05
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at Cycle 25	-4.70 score on a scale	Standard Deviation 26.16
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at Cycle 5	1.75 score on a scale	Standard Deviation 27.71
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at Cycle 19	-8.33 score on a scale	Standard Deviation 31.34
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at PT Visit 1	10.02 score on a scale	Standard Deviation 28.48
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at Cycle 12	-2.53 score on a scale	Standard Deviation 19.75
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at Cycle 20	-3.97 score on a scale	Standard Deviation 31.65
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Cycle 1 (Baseline)	26.67 score on a scale	Standard Deviation 30.32
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at Cycle 3	0.31 score on a scale	Standard Deviation 27.62
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at Cycle 20	5.95 score on a scale	Standard Deviation 19.47
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at Cycle 4	0.89 score on a scale	Standard Deviation 25.95
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at Cycle 21	-5.91 score on a scale	Standard Deviation 31.01
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at Cycle 6	1.11 score on a scale	Standard Deviation 27.62
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at Cycle 7	1.11 score on a scale	Standard Deviation 31.08
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at Cycle 17	-2.53 score on a scale	Standard Deviation 17.21
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea and Vomiting Scale: Cycle 1 (Baseline)	11.14 score on a scale	Standard Deviation 19.11
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at Cycle 22	-4.98 score on a scale	Standard Deviation 34.45
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea And Vomiting Scale: Change at Cycle 5	5.13 score on a scale	Standard Deviation 22.58
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at Cycle 8	1.15 score on a scale	Standard Deviation 30.21
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at Cycle 23	-6.35 score on a scale	Standard Deviation 36.84
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at Cycle 21	3.80 score on a scale	Standard Deviation 23.26
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at Cycle 9	1.11 score on a scale	Standard Deviation 29.78
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at Cycle 24	-7.78 score on a scale	Standard Deviation 33.82
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at Cycle 10	0.90 score on a scale	Standard Deviation 30.1
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at Cycle 10	0.11 score on a scale	Standard Deviation 19.93
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at Cycle 26	-7.48 score on a scale	Standard Deviation 34.87
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at Cycle 2	-0.50 score on a scale	Standard Deviation 19.04
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at Cycle 15	-1.81 score on a scale	Standard Deviation 28.96
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at Cycle 27	-10.08 score on a scale	Standard Deviation 33.76
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at Cycle 6	3.20 score on a scale	Standard Deviation 23.79
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at Cycle 8	-0.14 score on a scale	Standard Deviation 21.99
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at Cycle 16	-3.16 score on a scale	Standard Deviation 30.13
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at Cycle 28	-10.00 score on a scale	Standard Deviation 32.2
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at Cycle 18	-2.29 score on a scale	Standard Deviation 27.46
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at Cycle 27	-13.18 score on a scale	Standard Deviation 30.11
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at PT Visit 1	7.30 score on a scale	Standard Deviation 36.86
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at Cycle 28	-11.67 score on a scale	Standard Deviation 31.62
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at Cycle 19	-0.35 score on a scale	Standard Deviation 28.41
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at PT Visit 1	2.81 score on a scale	Standard Deviation 29.19
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at PT Visit 2	-0.33 score on a scale	Standard Deviation 33.83
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at PT Visit 2	5.67 score on a scale	Standard Deviation 29.23
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at Cycle 20	1.19 score on a scale	Standard Deviation 29.47
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Cycle 1 (Baseline)	87.95 score on a scale	Standard Deviation 17.32
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at Cycle 11	0.39 score on a scale	Standard Deviation 29.37
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at Cycle 23	-0.53 score on a scale	Standard Deviation 26.43
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at Cycle 12	-1.05 score on a scale	Standard Deviation 28.91
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at Cycle 13	-0.95 score on a scale	Standard Deviation 28.82
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at Cycle 2	-1.90 score on a scale	Standard Deviation 17.82
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at Cycle 14	-1.73 score on a scale	Standard Deviation 29.74
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at Cycle 25	3.21 score on a scale	Standard Deviation 27.42
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at Cycle 3	-0.83 score on a scale	Standard Deviation 17.11
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at Cycle 22	6.97 score on a scale	Standard Deviation 24.98
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at Cycle 17	-3.87 score on a scale	Standard Deviation 29.59
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at Cycle 4	-2.04 score on a scale	Standard Deviation 17.78
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at Cycle 26	2.72 score on a scale	Standard Deviation 28.74
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at Cycle 5	-3.04 score on a scale	Standard Deviation 19.09
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at Cycle 27	-3.10 score on a scale	Standard Deviation 23.92
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at Cycle 21	1.27 score on a scale	Standard Deviation 28.96
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at Cycle 6	-5.10 score on a scale	Standard Deviation 19.23
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at Cycle 22	2.49 score on a scale	Standard Deviation 26.79
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at Cycle 16	-1.45 score on a scale	Standard Deviation 20.42
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at Cycle 7	-4.34 score on a scale	Standard Deviation 19.52
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at Cycle 24	1.11 score on a scale	Standard Deviation 24.52
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at Cycle 28	-1.67 score on a scale	Standard Deviation 23.81
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at Cycle 8	-3.15 score on a scale	Standard Deviation 17.9
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at Cycle 10	6.63 score on a scale	Standard Deviation 23.97
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at PT Visit 1	1.70 score on a scale	Standard Deviation 29.66
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea And Vomiting Scale: Change at Cycle 12	-3.04 score on a scale	Standard Deviation 18.07
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea And Vomiting Scale: Change at Cycle 13	-4.02 score on a scale	Standard Deviation 16.29
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at Cycle 9	-2.22 score on a scale	Standard Deviation 18.53
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at PT Visit 2	1.98 score on a scale	Standard Deviation 26.17
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea And Vomiting Scale: Change at Cycle 17	-0.60 score on a scale	Standard Deviation 17.46
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at Cycle 10	-3.32 score on a scale	Standard Deviation 19.44
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea And Vomiting Scale: Change at Cycle 18	-0.65 score on a scale	Standard Deviation 16.9
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at Cycle 23	6.88 score on a scale	Standard Deviation 21.72
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at Cycle 11	-2.83 score on a scale	Standard Deviation 18.44
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea And Vomiting Scale: Change at Cycle 2	5.85 score on a scale	Standard Deviation 22.65
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea And Vomiting Scale: Change at Cycle 22	-3.48 score on a scale	Standard Deviation 19.14
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea And Vomiting Scale: Change at Cycle 23	-4.23 score on a scale	Standard Deviation 17.7
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea And Vomiting Scale: Change at Cycle 24	-4.72 score on a scale	Standard Deviation 16.26
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at Cycle 24	7.22 score on a scale	Standard Deviation 22.21
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea And Vomiting Scale: Change at Cycle 25	-4.17 score on a scale	Standard Deviation 20.84
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at Cycle 13	-1.79 score on a scale	Standard Deviation 19.04
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea And Vomiting Scale: Change at Cycle 26	-3.40 score on a scale	Standard Deviation 24.29
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea And Vomiting Scale: Change at Cycle 3	5.12 score on a scale	Standard Deviation 23.62
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea And Vomiting Scale: Change at Cycle 27	-5.04 score on a scale	Standard Deviation 22.58
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at Cycle 14	-1.98 score on a scale	Standard Deviation 19
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea And Vomiting Scale: Change at Cycle 28	-1.25 score on a scale	Standard Deviation 20.11
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at Cycle 19	-1.74 score on a scale	Standard Deviation 20.73
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea and Vomiting Scale: Change at PT Visit 1	4.68 score on a scale	Standard Deviation 22.2
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at Cycle 15	-1.15 score on a scale	Standard Deviation 18.47
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea and Vomiting Scale: Change at PT Visit 2	4.29 score on a scale	Standard Deviation 23.05
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea And Vomiting Scale: Change at Cycle 4	4.10 score on a scale	Standard Deviation 21.85
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Cycle 1 (Baseline)	23.92 score on a scale	Standard Deviation 25.92
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at Cycle 16	-2.73 score on a scale	Standard Deviation 17.16
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at Cycle 25	8.97 score on a scale	Standard Deviation 23.91
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at Cycle 2	-6.80 score on a scale	Standard Deviation 24.69
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea And Vomiting Scale: Change at Cycle 6	4.11 score on a scale	Standard Deviation 23.36
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at Cycle 3	-9.89 score on a scale	Standard Deviation 25.16
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at Cycle 18	-2.78 score on a scale	Standard Deviation 18.18
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at Cycle 4	-10.26 score on a scale	Standard Deviation 24.78
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea And Vomiting Scale: Change at Cycle 7	2.07 score on a scale	Standard Deviation 23.58
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at Cycle 19	-1.04 score on a scale	Standard Deviation 18.07
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at Cycle 6	-8.95 score on a scale	Standard Deviation 25.73
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at Cycle 21	1.27 score on a scale	Standard Deviation 22.29
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at Cycle 7	-10.95 score on a scale	Standard Deviation 26.13
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at Cycle 8	-9.97 score on a scale	Standard Deviation 25.8
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at Cycle 9	-9.29 score on a scale	Standard Deviation 24.83
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at Cycle 10	-9.41 score on a scale	Standard Deviation 26.1
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at Cycle 20	-2.18 score on a scale	Standard Deviation 19.67
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at Cycle 11	-10.33 score on a scale	Standard Deviation 25.77
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea And Vomiting Scale: Change at Cycle 8	-0.86 score on a scale	Standard Deviation 20.8
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at Cycle 21	-2.11 score on a scale	Standard Deviation 20.56
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at Cycle 13	-10.28 score on a scale	Standard Deviation 25.79
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea And Vomiting Scale: Change at Cycle 9	-2.54 score on a scale	Standard Deviation 20.85
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at Cycle 14	-10.49 score on a scale	Standard Deviation 25.49
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at Cycle 22	-4.73 score on a scale	Standard Deviation 18.98
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at Cycle 16	-9.91 score on a scale	Standard Deviation 22.94
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at Cycle 17	-7.59 score on a scale	Standard Deviation 25
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at Cycle 22	-1.99 score on a scale	Standard Deviation 22.38
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at Cycle 18	-8.82 score on a scale	Standard Deviation 23.42
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at Cycle 23	-2.38 score on a scale	Standard Deviation 19.6
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea And Vomiting Scale: Change at Cycle 10	-4.30 score on a scale	Standard Deviation 18.81
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at Cycle 24	-2.78 score on a scale	Standard Deviation 19.69
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at Cycle 21	-9.92 score on a scale	Standard Deviation 27.15
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at Cycle 24	1.11 score on a scale	Standard Deviation 22.1
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at Cycle 22	-7.71 score on a scale	Standard Deviation 26.96
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at Cycle 25	-5.45 score on a scale	Standard Deviation 16.41
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at Cycle 23	-10.85 score on a scale	Standard Deviation 22.03
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at Cycle 24	-10.00 score on a scale	Standard Deviation 24.39
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea And Vomiting Scale: Change at Cycle 11	-3.51 score on a scale	Standard Deviation 18.01
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at Cycle 25	-9.94 score on a scale	Standard Deviation 24.09
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at Cycle 26	-2.38 score on a scale	Standard Deviation 16.32
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at Cycle 26	-10.54 score on a scale	Standard Deviation 22.49
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at Cycle 12	-1.05 score on a scale	Standard Deviation 20.06
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at Cycle 27	-11.24 score on a scale	Standard Deviation 22.34
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at Cycle 27	-3.88 score on a scale	Standard Deviation 18.84
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at Cycle 28	-10.42 score on a scale	Standard Deviation 27.91
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at Cycle 25	0.64 score on a scale	Standard Deviation 21.38
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at PT Visit 1	1.13 score on a scale	Standard Deviation 27.27
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at PT Visit 2	-1.49 score on a scale	Standard Deviation 28.39
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at Cycle 28	-3.75 score on a scale	Standard Deviation 15.78
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at Cycle 2	-3.58 score on a scale	Standard Deviation 14.56
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at Cycle 26	5.44 score on a scale	Standard Deviation 21.89
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at Cycle 3	-2.99 score on a scale	Standard Deviation 17.19
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at Cycle 4	-3.28 score on a scale	Standard Deviation 18.87
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at Cycle 5	-3.10 score on a scale	Standard Deviation 19.35
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at PT Visit 1	-9.13 score on a scale	Standard Deviation 21.9
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at Cycle 6	-5.00 score on a scale	Standard Deviation 20.3
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea And Vomiting Scale: Change at Cycle 14	-3.46 score on a scale	Standard Deviation 19.54
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at Cycle 7	-3.66 score on a scale	Standard Deviation 20.75
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at PT Visit 2	-8.42 score on a scale	Standard Deviation 20.22
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at Cycle 8	-2.24 score on a scale	Standard Deviation 21.14
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea And Vomiting Scale: Change at Cycle 15	-3.59 score on a scale	Standard Deviation 16.34
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea And Vomiting Scale: Change at Cycle 16	-0.43 score on a scale	Standard Deviation 20.32
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at Cycle 18	0.13 score on a scale	Standard Deviation 19.74
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Cycle 1 (Baseline)	20.43 score on a scale	Standard Deviation 28.45
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at Cycle 20	0.71 score on a scale	Standard Deviation 21.08
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at Cycle 26	0.00 score on a scale	Standard Deviation 22.57
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at Cycle 21	0.42 score on a scale	Standard Deviation 22.2
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at Cycle 2	-5.39 score on a scale	Standard Deviation 27.05
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at Cycle 22	-2.79 score on a scale	Standard Deviation 21.9
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at Cycle 13	-0.80 score on a scale	Standard Deviation 20.65
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at Cycle 23	-1.48 score on a scale	Standard Deviation 21.47
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at Cycle 3	-7.48 score on a scale	Standard Deviation 28.98
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at Cycle 24	-2.67 score on a scale	Standard Deviation 22.27
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea And Vomiting Scale: Change at Cycle 19	-0.87 score on a scale	Standard Deviation 18.32
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at Cycle 25	-2.18 score on a scale	Standard Deviation 20.61
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at Cycle 4	-5.32 score on a scale	Standard Deviation 29.21
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at Cycle 26	-1.90 score on a scale	Standard Deviation 20.09
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea And Vomiting Scale: Change at Cycle 20	-1.79 score on a scale	Standard Deviation 18.48
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at Cycle 27	0.16 score on a scale	Standard Deviation 18.66
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at Cycle 5	-5.94 score on a scale	Standard Deviation 29.15
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at Cycle 28	-1.17 score on a scale	Standard Deviation 17.79
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea And Vomiting Scale: Change at Cycle 21	-1.05 score on a scale	Standard Deviation 20.03
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at PT Visit 1	-11.37 score on a scale	Standard Deviation 23.67
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at Cycle 6	-7.13 score on a scale	Standard Deviation 29.65
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at PT Visit 2	-11.49 score on a scale	Standard Deviation 24.31
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at Cycle 27	0.78 score on a scale	Standard Deviation 21.19
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Cycle 1 (Baseline)	59.77 score on a scale	Standard Deviation 22.88
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at Cycle 7	-8.13 score on a scale	Standard Deviation 30.11
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at Cycle 3	1.56 score on a scale	Standard Deviation 25.05
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at Cycle 27	3.88 score on a scale	Standard Deviation 22.07
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at Cycle 4	1.39 score on a scale	Standard Deviation 25.26
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at Cycle 8	-8.05 score on a scale	Standard Deviation 30.9
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at Cycle 5	1.17 score on a scale	Standard Deviation 25.7
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at Cycle 5	-8.86 score on a scale	Standard Deviation 25.88
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at Cycle 6	0.68 score on a scale	Standard Deviation 27.89
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at Cycle 9	-10.00 score on a scale	Standard Deviation 27.1
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at Cycle 7	1.83 score on a scale	Standard Deviation 27.81
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at PT Visit 1	6.97 score on a scale	Standard Deviation 26.98
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at Cycle 8	3.06 score on a scale	Standard Deviation 27.09
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at Cycle 10	-9.32 score on a scale	Standard Deviation 29.56
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at Cycle 9	4.39 score on a scale	Standard Deviation 26.25
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at Cycle 28	7.50 score on a scale	Standard Deviation 27.72
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at Cycle 10	4.80 score on a scale	Standard Deviation 25.35
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at Cycle 11	-9.16 score on a scale	Standard Deviation 29.6
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at Cycle 11	5.78 score on a scale	Standard Deviation 26.62
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at Cycle 12	3.11 score on a scale	Standard Deviation 24.89
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at Cycle 12	-10.27 score on a scale	Standard Deviation 23.1
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at Cycle 13	3.51 score on a scale	Standard Deviation 23.82
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at Cycle 12	-10.27 score on a scale	Standard Deviation 29.04
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at Cycle 14	5.97 score on a scale	Standard Deviation 23.09
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Cycle 1 (Baseline)	76.90 score on a scale	Standard Deviation 20.21
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at Cycle 15	4.26 score on a scale	Standard Deviation 25.98
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at Cycle 13	-11.19 score on a scale	Standard Deviation 29.55
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at Cycle 15	-11.15 score on a scale	Standard Deviation 22.86
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at Cycle 17	2.93 score on a scale	Standard Deviation 24.84
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at Cycle 14	-11.60 score on a scale	Standard Deviation 27.11
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at Cycle 18	3.02 score on a scale	Standard Deviation 23.88
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at PT Visit 1	8.14 score on a scale	Standard Deviation 26
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at Cycle 19	3.25 score on a scale	Standard Deviation 26.39
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at Cycle 15	-10.51 score on a scale	Standard Deviation 26.59
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at Cycle 20	5.12 score on a scale	Standard Deviation 24.2
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at Cycle 19	-8.16 score on a scale	Standard Deviation 25.13
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at Cycle 21	5.38 score on a scale	Standard Deviation 23.87
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at Cycle 16	-8.62 score on a scale	Standard Deviation 24.91
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at Cycle 22	3.79 score on a scale	Standard Deviation 22.56
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at Cycle 20	-6.94 score on a scale	Standard Deviation 25.9
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at Cycle 23	4.03 score on a scale	Standard Deviation 23.85
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at Cycle 17	-8.33 score on a scale	Standard Deviation 24.3
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at Cycle 24	4.24 score on a scale	Standard Deviation 22.66
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at Cycle 2	3.53 score on a scale	Standard Deviation 16.84
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at Cycle 25	3.59 score on a scale	Standard Deviation 22.38
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at Cycle 18	-7.52 score on a scale	Standard Deviation 22.93
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at Cycle 3	2.65 score on a scale	Standard Deviation 18.63
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at Cycle 27	7.54 score on a scale	Standard Deviation 23.19
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at Cycle 19	-3.47 score on a scale	Standard Deviation 25.81
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at Cycle 28	4.49 score on a scale	Standard Deviation 22.69
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at Cycle 15	3.33 score on a scale	Standard Deviation 23.79
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at PT Visit 1	-7.24 score on a scale	Standard Deviation 27.24
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at Cycle 20	-3.97 score on a scale	Standard Deviation 26.08
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at PT Visit 2	-2.72 score on a scale	Standard Deviation 27.46
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Cycle 1 (Baseline)	80.86 score on a scale	Standard Deviation 19.53
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Cycle 1 (Baseline)	77.06 score on a scale	Standard Deviation 27.02
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at Cycle 21	-3.80 score on a scale	Standard Deviation 29.23
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at Cycle 2	-3.78 score on a scale	Standard Deviation 24.99
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at Cycle 22	-4.98 score on a scale	Standard Deviation 28.58
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at Cycle 3	-3.62 score on a scale	Standard Deviation 25.96
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at Cycle 5	2.62 score on a scale	Standard Deviation 19.97
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at Cycle 4	-4.64 score on a scale	Standard Deviation 27.69
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at Cycle 23	-6.35 score on a scale	Standard Deviation 28.62
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at Cycle 5	-4.72 score on a scale	Standard Deviation 27.68
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at Cycle 6	1.01 score on a scale	Standard Deviation 19.64
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at Cycle 24	-7.78 score on a scale	Standard Deviation 27.01
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at Cycle 7	-4.82 score on a scale	Standard Deviation 29.75
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at Cycle 9	-1.59 score on a scale	Standard Deviation 20.21
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at Cycle 8	-1.85 score on a scale	Standard Deviation 28.87
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at Cycle 25	-7.05 score on a scale	Standard Deviation 29.77
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at Cycle 9	-1.19 score on a scale	Standard Deviation 28.57
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at Cycle 7	1.72 score on a scale	Standard Deviation 21.09
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at Cycle 10	-1.79 score on a scale	Standard Deviation 28.1
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at Cycle 26	-6.12 score on a scale	Standard Deviation 30.94
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at Cycle 11	-0.78 score on a scale	Standard Deviation 28.34
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at PT Visit 2	7.26 score on a scale	Standard Deviation 25.65
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at Cycle 12	-1.05 score on a scale	Standard Deviation 27.28
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at Cycle 27	-7.75 score on a scale	Standard Deviation 28.95
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at Cycle 13	-2.01 score on a scale	Standard Deviation 26.61
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at Cycle 17	-0.46 score on a scale	Standard Deviation 19.43
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at Cycle 14	-0.86 score on a scale	Standard Deviation 27.27
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at Cycle 28	-6.67 score on a scale	Standard Deviation 26.37
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at Cycle 15	-1.03 score on a scale	Standard Deviation 27.51
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at Cycle 8	3.43 score on a scale	Standard Deviation 20.66
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at Cycle 16	-3.16 score on a scale	Standard Deviation 28.73
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at PT Visit 1	-6.78 score on a scale	Standard Deviation 31.45
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at Cycle 17	-1.04 score on a scale	Standard Deviation 26.69
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at Cycle 19	1.39 score on a scale	Standard Deviation 19.82
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at Cycle 18	-0.16 score on a scale	Standard Deviation 27.1
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at PT Visit 2	-6.93 score on a scale	Standard Deviation 28.41
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at Cycle 19	1.04 score on a scale	Standard Deviation 27.55
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at Cycle 11	0.35 score on a scale	Standard Deviation 19.43
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at Cycle 20	-1.19 score on a scale	Standard Deviation 30.04
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Cycle 1 (Baseline)	8.87 score on a scale	Standard Deviation 17.7
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at Cycle 21	-0.84 score on a scale	Standard Deviation 28.98
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at Cycle 9	4.72 score on a scale	Standard Deviation 20.1
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at Cycle 22	-2.24 score on a scale	Standard Deviation 27.96
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at Cycle 2	15.12 score on a scale	Standard Deviation 30.42
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at Cycle 23	-3.44 score on a scale	Standard Deviation 30.11
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at Cycle 2	1.81 score on a scale	Standard Deviation 23.35
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at Cycle 3	14.64 score on a scale	Standard Deviation 27.71
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at Cycle 25	-3.53 score on a scale	Standard Deviation 29.21
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Cycle 1 (Baseline)	12.07 score on a scale	Standard Deviation 17.99
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at Cycle 26	-1.36 score on a scale	Standard Deviation 28.02
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at Cycle 4	14.13 score on a scale	Standard Deviation 27.15
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at Cycle 27	-1.55 score on a scale	Standard Deviation 30.82
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at Cycle 16	3.12 score on a scale	Standard Deviation 25.16
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at Cycle 28	-0.42 score on a scale	Standard Deviation 27.86
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at Cycle 5	13.17 score on a scale	Standard Deviation 25.47
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at PT Visit 1	-14.61 score on a scale	Standard Deviation 30.41
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at Cycle 26	7.27 score on a scale	Standard Deviation 24.55
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at Cycle 6	-6.13 score on a scale	Standard Deviation 28.94
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Cycle 1 (Baseline)	77.96 score on a scale	Standard Deviation 24.09
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at Cycle 23	-1.59 score on a scale	Standard Deviation 21.94
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at Cycle 2	-3.45 score on a scale	Standard Deviation 24.07
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at Cycle 24	-4.44 score on a scale	Standard Deviation 29.73
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at Cycle 3	-4.62 score on a scale	Standard Deviation 25.25
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at Cycle 6	14.81 score on a scale	Standard Deviation 27.01
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at Cycle 4	-2.59 score on a scale	Standard Deviation 25.08
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at PT Visit 2	-10.73 score on a scale	Standard Deviation 31.94
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at Cycle 5	-5.54 score on a scale	Standard Deviation 27.03
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at Cycle 7	12.26 score on a scale	Standard Deviation 23.74
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at Cycle 6	-5.72 score on a scale	Standard Deviation 27.87
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at Cycle 14	-0.02 score on a scale	Standard Deviation 20.14
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at Cycle 7	-2.69 score on a scale	Standard Deviation 27.13
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at Cycle 8	8.91 score on a scale	Standard Deviation 23.56
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at Cycle 8	-1.72 score on a scale	Standard Deviation 26.93
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at Cycle 15	6.03 score on a scale	Standard Deviation 22.13
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at Cycle 9	0.56 score on a scale	Standard Deviation 27.59
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at Cycle 9	6.83 score on a scale	Standard Deviation 23.76
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at Cycle 10	-0.81 score on a scale	Standard Deviation 27.31
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at Cycle 3	-0.31 score on a scale	Standard Deviation 20.18
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at Cycle 11	0.58 score on a scale	Standard Deviation 27.35
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at Cycle 15	0.41 score on a scale	Standard Deviation 18.91
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at Cycle 12	0.52 score on a scale	Standard Deviation 28.59
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at Cycle 11	5.26 score on a scale	Standard Deviation 21.8
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at Cycle 13	0.83 score on a scale	Standard Deviation 25.31
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at Cycle 17	2.68 score on a scale	Standard Deviation 21.05
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at Cycle 14	1.98 score on a scale	Standard Deviation 26.71
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at Cycle 12	3.98 score on a scale	Standard Deviation 22.3
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at Cycle 15	1.79 score on a scale	Standard Deviation 27.24
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at Cycle 13	4.29 score on a scale	Standard Deviation 24.27
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at Cycle 16	-0.72 score on a scale	Standard Deviation 25.76
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Cycle 1 (Baseline)	26.68 score on a scale	Standard Deviation 28.65
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at Cycle 17	-0.45 score on a scale	Standard Deviation 26.51
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at Cycle 14	3.95 score on a scale	Standard Deviation 24.45
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at Cycle 18	-0.98 score on a scale	Standard Deviation 25.99
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at Cycle 16	5.46 score on a scale	Standard Deviation 21.06
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at Cycle 19	2.26 score on a scale	Standard Deviation 26.56
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at Cycle 17	6.01 score on a scale	Standard Deviation 23.55
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at Cycle 20	1.59 score on a scale	Standard Deviation 27.09
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at Cycle 2	6.57 score on a scale	Standard Deviation 33.18
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at Cycle 21	1.27 score on a scale	Standard Deviation 28.09
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at Cycle 28	1.67 score on a scale	Standard Deviation 21.28
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at Cycle 22	1.24 score on a scale	Standard Deviation 27.72
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at Cycle 16	-1.08 score on a scale	Standard Deviation 19.85
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at Cycle 23	6.08 score on a scale	Standard Deviation 27.32
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at PT Visit 2	3.30 score on a scale	Standard Deviation 23.81
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at Cycle 24	5.83 score on a scale	Standard Deviation 25.64
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at Cycle 4	1.23 score on a scale	Standard Deviation 20.31
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at Cycle 25	1.60 score on a scale	Standard Deviation 27.27
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at Cycle 4	3.10 score on a scale	Standard Deviation 21.11
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at Cycle 26	3.74 score on a scale	Standard Deviation 26.19
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at Cycle 5	2.58 score on a scale	Standard Deviation 20.62
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at Cycle 27	5.81 score on a scale	Standard Deviation 24.37
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at Cycle 13	-1.43 score on a scale	Standard Deviation 20.34
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at Cycle 28	6.25 score on a scale	Standard Deviation 23.48
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at Cycle 14	-1.98 score on a scale	Standard Deviation 19
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at PT Visit 1	-9.13 score on a scale	Standard Deviation 26.47
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at Cycle 10	3.72 score on a scale	Standard Deviation 21.76
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at PT Visit 2	-5.45 score on a scale	Standard Deviation 28.49
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at Cycle 3	3.63 score on a scale	Standard Deviation 36.19
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Cycle 1 (Baseline)	22.94 score on a scale	Standard Deviation 28
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at Cycle 11	5.85 score on a scale	Standard Deviation 19.64
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at Cycle 2	-0.69 score on a scale	Standard Deviation 26.82
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at Cycle 20	3.47 score on a scale	Standard Deviation 26.92
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at Cycle 3	-3.53 score on a scale	Standard Deviation 27.03
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at Cycle 12	4.93 score on a scale	Standard Deviation 21.38
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at Cycle 4	-2.88 score on a scale	Standard Deviation 28.14
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at Cycle 4	5.24 score on a scale	Standard Deviation 34.2
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at Cycle 5	-2.21 score on a scale	Standard Deviation 29.27
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at Cycle 13	5.00 score on a scale	Standard Deviation 23.07
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at Cycle 6	-2.94 score on a scale	Standard Deviation 28.63
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at Cycle 14	5.93 score on a scale	Standard Deviation 22.9
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at Cycle 7	-4.56 score on a scale	Standard Deviation 28.42
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at Cycle 8	-6.13 score on a scale	Standard Deviation 27.72
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at Cycle 9	-8.97 score on a scale	Standard Deviation 25.69
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at Cycle 25	-7.05 score on a scale	Standard Deviation 35.14
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at Cycle 10	-8.24 score on a scale	Standard Deviation 26.69
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at Cycle 16	5.17 score on a scale	Standard Deviation 23.2
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at Cycle 11	-8.97 score on a scale	Standard Deviation 28.19
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at Cycle 18	3.68 score on a scale	Standard Deviation 24.11
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at Cycle 12	-8.81 score on a scale	Standard Deviation 27.67
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at Cycle 5	4.55 score on a scale	Standard Deviation 36.5
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at Cycle 13	-10.17 score on a scale	Standard Deviation 26.71
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at Cycle 19	4.69 score on a scale	Standard Deviation 26.01
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at Cycle 14	-9.14 score on a scale	Standard Deviation 26.84
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at Cycle 18	3.59 score on a scale	Standard Deviation 21.95
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at Cycle 15	-9.74 score on a scale	Standard Deviation 28.89
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at Cycle 21	4.54 score on a scale	Standard Deviation 26.55
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at Cycle 16	-8.91 score on a scale	Standard Deviation 26.14
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at Cycle 6	3.94 score on a scale	Standard Deviation 36.07
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at Cycle 17	-11.01 score on a scale	Standard Deviation 26.62
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at Cycle 22	5.35 score on a scale	Standard Deviation 28.67
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at Cycle 18	-8.82 score on a scale	Standard Deviation 28.12
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at Cycle 26	5.44 score on a scale	Standard Deviation 27.77
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at Cycle 19	-11.46 score on a scale	Standard Deviation 29.35
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at Cycle 23	5.82 score on a scale	Standard Deviation 28.42
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at Cycle 20	-10.32 score on a scale	Standard Deviation 27.37
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at Cycle 24	5.28 score on a scale	Standard Deviation 26.22
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at Cycle 21	-11.81 score on a scale	Standard Deviation 27.24
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at Cycle 7	2.07 score on a scale	Standard Deviation 38.05
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at Cycle 22	-10.95 score on a scale	Standard Deviation 31.46
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at Cycle 25	5.93 score on a scale	Standard Deviation 25.48
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at Cycle 23	-10.58 score on a scale	Standard Deviation 34.82
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at Cycle 27	7.56 score on a scale	Standard Deviation 28.34
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at Cycle 24	-9.44 score on a scale	Standard Deviation 31.94
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at Cycle 8	-2.42 score on a scale	Standard Deviation 33.81
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at Cycle 25	-10.26 score on a scale	Standard Deviation 28.42
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at Cycle 28	7.08 score on a scale	Standard Deviation 25.43
Pertuzumab + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at Cycle 26	-9.52 score on a scale	Standard Deviation 32.63
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at Cycle 28	7.05 score on a scale	Standard Deviation 18.96
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at Cycle 10	-0.27 score on a scale	Standard Deviation 17.16
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at Cycle 11	0.27 score on a scale	Standard Deviation 17.09
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at Cycle 13	0.27 score on a scale	Standard Deviation 17.41
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at Cycle 21	-9.26 score on a scale	Standard Deviation 25.42
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at Cycle 12	1.92 score on a scale	Standard Deviation 19.97
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at Cycle 14	0.98 score on a scale	Standard Deviation 20.15
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at Cycle 15	1.02 score on a scale	Standard Deviation 19.42
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at Cycle 16	3.14 score on a scale	Standard Deviation 15.1
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at Cycle 17	2.25 score on a scale	Standard Deviation 14.94
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at Cycle 19	2.02 score on a scale	Standard Deviation 16.41
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at Cycle 20	3.70 score on a scale	Standard Deviation 17.05
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at Cycle 21	1.85 score on a scale	Standard Deviation 16.4
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at Cycle 22	4.26 score on a scale	Standard Deviation 17.88
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at Cycle 25	2.78 score on a scale	Standard Deviation 14.64
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at Cycle 26	5.21 score on a scale	Standard Deviation 20.93
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at PT Visit 1	1.98 score on a scale	Standard Deviation 24.35
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at PT Visit 2	4.24 score on a scale	Standard Deviation 29.65
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Cycle 1 (Baseline)	12.65 score on a scale	Standard Deviation 20.2
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at Cycle 3	-0.32 score on a scale	Standard Deviation 20.38
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at Cycle 5	1.39 score on a scale	Standard Deviation 21.18
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at Cycle 6	0.39 score on a scale	Standard Deviation 20.55
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at Cycle 7	0.59 score on a scale	Standard Deviation 20.07
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at Cycle 9	0.17 score on a scale	Standard Deviation 18.95
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at Cycle 12	-0.71 score on a scale	Standard Deviation 18.95
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at Cycle 13	-1.20 score on a scale	Standard Deviation 16.77
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at Cycle 14	-2.61 score on a scale	Standard Deviation 17.98
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at Cycle 15	2.72 score on a scale	Standard Deviation 18.95
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at Cycle 16	1.18 score on a scale	Standard Deviation 18.86
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at Cycle 17	0.90 score on a scale	Standard Deviation 19.87
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at Cycle 18	-2.35 score on a scale	Standard Deviation 18.1
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at Cycle 19	0.51 score on a scale	Standard Deviation 18.15
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at Cycle 24	-1.67 score on a scale	Standard Deviation 12.96
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at Cycle 25	-3.70 score on a scale	Standard Deviation 15.49
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at Cycle 26	1.04 score on a scale	Standard Deviation 23.16
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at Cycle 28	3.85 score on a scale	Standard Deviation 17.2
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at PT Visit 2	9.39 score on a scale	Standard Deviation 26.76
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Cycle 1 (Baseline)	76.56 score on a scale	Standard Deviation 19.84
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at Cycle 3	3.96 score on a scale	Standard Deviation 19.95
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at Cycle 7	4.41 score on a scale	Standard Deviation 20.18
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at Cycle 8	5.66 score on a scale	Standard Deviation 19.63
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at Cycle 9	4.78 score on a scale	Standard Deviation 19.45
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at Cycle 13	5.18 score on a scale	Standard Deviation 17.95
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at Cycle 15	5.19 score on a scale	Standard Deviation 19.61
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at Cycle 16	5.29 score on a scale	Standard Deviation 20.81
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at Cycle 17	6.31 score on a scale	Standard Deviation 18.7
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at Cycle 19	5.56 score on a scale	Standard Deviation 18.68
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at Cycle 23	6.63 score on a scale	Standard Deviation 21
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at Cycle 25	8.80 score on a scale	Standard Deviation 20.89
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at Cycle 7	0.97 score on a scale	Standard Deviation 23.44
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at Cycle 24	-12.50 score on a scale	Standard Deviation 24.29
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at Cycle 27	-5.36 score on a scale	Standard Deviation 23.87
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at Cycle 28	-4.70 score on a scale	Standard Deviation 26.14
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Cycle 1 (Baseline)	26.21 score on a scale	Standard Deviation 29.78
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at Cycle 2	-2.46 score on a scale	Standard Deviation 25.46
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at Cycle 5	2.58 score on a scale	Standard Deviation 26.46
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at Cycle 6	0.92 score on a scale	Standard Deviation 26.36
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at Cycle 7	0.30 score on a scale	Standard Deviation 26.41
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at Cycle 12	-0.97 score on a scale	Standard Deviation 26.39
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at Cycle 25	-4.63 score on a scale	Standard Deviation 25.39
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at Cycle 27	1.15 score on a scale	Standard Deviation 24.37
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at PT Visit 1	1.33 score on a scale	Standard Deviation 26.21
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea and Vomiting Scale: Cycle 1 (Baseline)	11.92 score on a scale	Standard Deviation 18.76
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea And Vomiting Scale: Change at Cycle 2	4.08 score on a scale	Standard Deviation 22.25
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea And Vomiting Scale: Change at Cycle 3	5.06 score on a scale	Standard Deviation 21.14
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea And Vomiting Scale: Change at Cycle 5	5.15 score on a scale	Standard Deviation 23.81
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea And Vomiting Scale: Change at Cycle 7	2.49 score on a scale	Standard Deviation 22.31
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea And Vomiting Scale: Change at Cycle 9	-2.98 score on a scale	Standard Deviation 19.78
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea And Vomiting Scale: Change at Cycle 10	-2.81 score on a scale	Standard Deviation 20.57
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea And Vomiting Scale: Change at Cycle 11	-3.66 score on a scale	Standard Deviation 20.04
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea And Vomiting Scale: Change at Cycle 12	-3.45 score on a scale	Standard Deviation 20.34
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea And Vomiting Scale: Change at Cycle 13	-3.60 score on a scale	Standard Deviation 19.25
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea And Vomiting Scale: Change at Cycle 16	-2.55 score on a scale	Standard Deviation 20
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea And Vomiting Scale: Change at Cycle 18	-3.52 score on a scale	Standard Deviation 18.24
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea And Vomiting Scale: Change at Cycle 22	-8.16 score on a scale	Standard Deviation 18.99
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea And Vomiting Scale: Change at Cycle 23	-6.44 score on a scale	Standard Deviation 24.7
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at Cycle 8	-8.53 score on a scale	Standard Deviation 22.86
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at Cycle 9	-7.82 score on a scale	Standard Deviation 22.98
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at Cycle 14	-5.56 score on a scale	Standard Deviation 23.37
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at Cycle 16	-4.71 score on a scale	Standard Deviation 23.66
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at Cycle 23	-7.95 score on a scale	Standard Deviation 26.29
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at PT Visit 1	2.06 score on a scale	Standard Deviation 28.7
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at PT Visit 2	5.45 score on a scale	Standard Deviation 29.96
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at Cycle 3	-3.92 score on a scale	Standard Deviation 17.03
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at Cycle 4	-3.50 score on a scale	Standard Deviation 17.99
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at Cycle 12	0.89 score on a scale	Standard Deviation 16.35
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at Cycle 15	-0.95 score on a scale	Standard Deviation 17.99
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at Cycle 17	-0.81 score on a scale	Standard Deviation 17.55
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at Cycle 19	1.31 score on a scale	Standard Deviation 14.38
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Cycle 1 (Baseline)	59.90 score on a scale	Standard Deviation 22.11
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at Cycle 11	3.82 score on a scale	Standard Deviation 23.75
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at Cycle 7	-4.82 score on a scale	Standard Deviation 32.98
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at Cycle 8	-6.45 score on a scale	Standard Deviation 30.75
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at Cycle 14	1.70 score on a scale	Standard Deviation 18.09
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at Cycle 10	1.00 score on a scale	Standard Deviation 16.99
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Cycle 1 (Baseline)	27.59 score on a scale	Standard Deviation 29.96
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at Cycle 11	-1.29 score on a scale	Standard Deviation 17.77
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at Cycle 2	0.97 score on a scale	Standard Deviation 35.86
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at Cycle 3	3.81 score on a scale	Standard Deviation 36.76
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at Cycle 4	0.79 score on a scale	Standard Deviation 34.33
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at Cycle 5	2.90 score on a scale	Standard Deviation 35.85
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at Cycle 6	-0.39 score on a scale	Standard Deviation 36.86
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at Cycle 7	1.61 score on a scale	Standard Deviation 35.98
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at Cycle 8	-3.69 score on a scale	Standard Deviation 34.2
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at Cycle 9	-4.76 score on a scale	Standard Deviation 31.67
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at Cycle 10	-6.63 score on a scale	Standard Deviation 28.48
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at Cycle 11	-9.68 score on a scale	Standard Deviation 27.38
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at Cycle 12	-9.05 score on a scale	Standard Deviation 28.51
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at Cycle 13	-10.81 score on a scale	Standard Deviation 29.18
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at Cycle 14	-12.09 score on a scale	Standard Deviation 30.32
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at Cycle 15	-9.18 score on a scale	Standard Deviation 29.81
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at Cycle 16	-10.59 score on a scale	Standard Deviation 28.74
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at Cycle 20	-1.06 score on a scale	Standard Deviation 16.9
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at Cycle 17	-9.91 score on a scale	Standard Deviation 29.05
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at Cycle 18	-14.08 score on a scale	Standard Deviation 27.98
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at Cycle 19	-13.13 score on a scale	Standard Deviation 28.57
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at Cycle 20	-13.23 score on a scale	Standard Deviation 29.66
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at Cycle 21	-14.20 score on a scale	Standard Deviation 32.76
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at Cycle 22	-16.31 score on a scale	Standard Deviation 29.38
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at Cycle 23	-11.36 score on a scale	Standard Deviation 35.9
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at Cycle 24	-13.33 score on a scale	Standard Deviation 30
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at Cycle 25	-12.04 score on a scale	Standard Deviation 31.02
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at Cycle 26	-12.50 score on a scale	Standard Deviation 32.52
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at Cycle 27	-9.20 score on a scale	Standard Deviation 28.03
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at Cycle 28	-11.54 score on a scale	Standard Deviation 29.73
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at PT Visit 1	2.64 score on a scale	Standard Deviation 33.14
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Appetite Loss: Change at PT Visit 2	4.55 score on a scale	Standard Deviation 34.53
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Cycle 1 (Baseline)	88.22 score on a scale	Standard Deviation 16.18
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at Cycle 2	-1.81 score on a scale	Standard Deviation 16.93
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at Cycle 3	-3.17 score on a scale	Standard Deviation 18.3
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at Cycle 4	-2.99 score on a scale	Standard Deviation 19.28
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at Cycle 5	-4.59 score on a scale	Standard Deviation 19.59
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at Cycle 6	-3.84 score on a scale	Standard Deviation 19
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at Cycle 7	-4.31 score on a scale	Standard Deviation 19.09
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at Cycle 8	-3.30 score on a scale	Standard Deviation 17.59
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at Cycle 9	-4.59 score on a scale	Standard Deviation 18.53
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at Cycle 10	-3.11 score on a scale	Standard Deviation 18.5
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at Cycle 11	-3.44 score on a scale	Standard Deviation 17.06
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at Cycle 12	-2.52 score on a scale	Standard Deviation 18.16
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at Cycle 13	-3.60 score on a scale	Standard Deviation 17.89
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at Cycle 14	-2.29 score on a scale	Standard Deviation 17.56
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at Cycle 15	-2.38 score on a scale	Standard Deviation 16.05
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at Cycle 16	-2.55 score on a scale	Standard Deviation 17.16
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at Cycle 17	-1.13 score on a scale	Standard Deviation 15.44
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at Cycle 18	0.47 score on a scale	Standard Deviation 16.42
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at Cycle 19	0.00 score on a scale	Standard Deviation 14.62
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at Cycle 20	0.79 score on a scale	Standard Deviation 15.68
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at Cycle 21	0.62 score on a scale	Standard Deviation 16.5
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at Cycle 22	-0.71 score on a scale	Standard Deviation 18.04
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at Cycle 23	1.14 score on a scale	Standard Deviation 17.75
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at Cycle 24	1.25 score on a scale	Standard Deviation 16.18
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at Cycle 25	-0.93 score on a scale	Standard Deviation 18.66
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at Cycle 26	-1.56 score on a scale	Standard Deviation 18.63
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at Cycle 27	-1.15 score on a scale	Standard Deviation 18.33
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at Cycle 28	0.00 score on a scale	Standard Deviation 20
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at PT Visit 1	-9.16 score on a scale	Standard Deviation 20.02
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Cognitive Functional Scale: Change at PT Visit 2	-11.21 score on a scale	Standard Deviation 22.48
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at Cycle 21	-0.62 score on a scale	Standard Deviation 19.95
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Cycle 1 (Baseline)	18.41 score on a scale	Standard Deviation 27.13
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at Cycle 2	0.29 score on a scale	Standard Deviation 27.23
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at Cycle 3	-2.11 score on a scale	Standard Deviation 27.65
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at Cycle 4	-3.73 score on a scale	Standard Deviation 28.26
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at Cycle 5	-1.28 score on a scale	Standard Deviation 27.64
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at Cycle 6	-2.33 score on a scale	Standard Deviation 30.24
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at Cycle 7	-4.09 score on a scale	Standard Deviation 29.06
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at Cycle 8	-4.45 score on a scale	Standard Deviation 27.32
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at Cycle 9	-5.61 score on a scale	Standard Deviation 26.74
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at Cycle 10	-7.43 score on a scale	Standard Deviation 26.81
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at Cycle 11	-6.88 score on a scale	Standard Deviation 27.84
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at Cycle 12	-7.25 score on a scale	Standard Deviation 25.39
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at Cycle 13	-5.76 score on a scale	Standard Deviation 26.27
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at Cycle 14	-6.21 score on a scale	Standard Deviation 26
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at Cycle 15	-7.14 score on a scale	Standard Deviation 24.52
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at Cycle 16	-7.45 score on a scale	Standard Deviation 25.39
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at Cycle 17	-5.86 score on a scale	Standard Deviation 18.59
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at Cycle 18	-6.57 score on a scale	Standard Deviation 26.2
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at Cycle 19	-3.03 score on a scale	Standard Deviation 25.97
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at Cycle 20	-4.76 score on a scale	Standard Deviation 26.68
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at Cycle 22	-8.51 score on a scale	Standard Deviation 27.34
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at Cycle 23	-8.33 score on a scale	Standard Deviation 26.04
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at Cycle 24	-10.00 score on a scale	Standard Deviation 26.37
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at Cycle 25	-9.26 score on a scale	Standard Deviation 28.3
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at Cycle 26	-6.25 score on a scale	Standard Deviation 23.09
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at Cycle 27	-10.34 score on a scale	Standard Deviation 26.88
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at Cycle 28	-6.41 score on a scale	Standard Deviation 21.12
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at PT Visit 1	-4.62 score on a scale	Standard Deviation 26.19
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Constipation Symptom Scale: Change at PT Visit 2	-0.91 score on a scale	Standard Deviation 31.11
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Cycle 1 (Baseline)	9.16 score on a scale	Standard Deviation 18.87
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at Cycle 2	5.20 score on a scale	Standard Deviation 23.79
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at Cycle 3	4.99 score on a scale	Standard Deviation 26.1
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at Cycle 4	4.63 score on a scale	Standard Deviation 24.07
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at Cycle 5	4.99 score on a scale	Standard Deviation 23.7
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at Cycle 22	0.71 score on a scale	Standard Deviation 14.73
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at Cycle 23	1.52 score on a scale	Standard Deviation 14.3
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at Cycle 6	2.47 score on a scale	Standard Deviation 23.76
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at Cycle 7	2.92 score on a scale	Standard Deviation 23.44
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at Cycle 8	2.61 score on a scale	Standard Deviation 23.53
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at Cycle 9	2.04 score on a scale	Standard Deviation 21.25
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at Cycle 10	0.60 score on a scale	Standard Deviation 20.91
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at Cycle 11	2.60 score on a scale	Standard Deviation 20.36
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at Cycle 13	1.50 score on a scale	Standard Deviation 19.27
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at Cycle 18	3.29 score on a scale	Standard Deviation 17.95
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at Cycle 27	3.45 score on a scale	Standard Deviation 22.44
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at PT Visit 1	6.77 score on a scale	Standard Deviation 23.82
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at Cycle 2	3.05 score on a scale	Standard Deviation 18.49
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at Cycle 4	3.67 score on a scale	Standard Deviation 20.44
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at Cycle 5	2.74 score on a scale	Standard Deviation 21.72
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at Cycle 6	4.93 score on a scale	Standard Deviation 21
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at Cycle 10	6.74 score on a scale	Standard Deviation 18.13
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at Cycle 11	4.96 score on a scale	Standard Deviation 19.21
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at Cycle 12	5.24 score on a scale	Standard Deviation 19.14
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at Cycle 14	6.29 score on a scale	Standard Deviation 19.03
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at Cycle 18	5.87 score on a scale	Standard Deviation 19.39
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at Cycle 20	5.42 score on a scale	Standard Deviation 17.91
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at Cycle 21	6.48 score on a scale	Standard Deviation 22
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at Cycle 22	6.91 score on a scale	Standard Deviation 18.66
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at Cycle 24	8.54 score on a scale	Standard Deviation 19.57
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at Cycle 26	5.99 score on a scale	Standard Deviation 16.15
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at Cycle 27	5.75 score on a scale	Standard Deviation 18.51
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at Cycle 9	-0.75 score on a scale	Standard Deviation 18.44
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at PT Visit 1	-3.92 score on a scale	Standard Deviation 23.28
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Emotional Functional Scale: Change at PT Visit 2	-4.47 score on a scale	Standard Deviation 23.34
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Cycle 1 (Baseline)	32.27 score on a scale	Standard Deviation 21.92
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at Cycle 2	2.32 score on a scale	Standard Deviation 21.57
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at Cycle 3	3.19 score on a scale	Standard Deviation 22.97
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at Cycle 4	1.58 score on a scale	Standard Deviation 24.04
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at Cycle 5	3.05 score on a scale	Standard Deviation 24.29
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at Cycle 6	2.62 score on a scale	Standard Deviation 23.68
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at Cycle 8	-1.18 score on a scale	Standard Deviation 22.74
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at Cycle 9	-2.01 score on a scale	Standard Deviation 22.84
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at Cycle 10	-3.08 score on a scale	Standard Deviation 22.41
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at Cycle 11	-3.44 score on a scale	Standard Deviation 21.21
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at Cycle 12	-4.60 score on a scale	Standard Deviation 24.39
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at Cycle 13	-4.50 score on a scale	Standard Deviation 21.47
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at Cycle 14	-6.54 score on a scale	Standard Deviation 22.89
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at Cycle 15	-4.99 score on a scale	Standard Deviation 22.4
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at Cycle 16	-6.93 score on a scale	Standard Deviation 21.89
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at Cycle 17	-3.45 score on a scale	Standard Deviation 21.91
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at Cycle 18	-8.92 score on a scale	Standard Deviation 20.54
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at Cycle 19	-9.01 score on a scale	Standard Deviation 20.71
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at Cycle 20	-6.53 score on a scale	Standard Deviation 21.83
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at Cycle 21	-7.41 score on a scale	Standard Deviation 23.45
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at Cycle 22	-10.64 score on a scale	Standard Deviation 22.22
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at Cycle 23	-9.60 score on a scale	Standard Deviation 28.01
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at Cycle 25	-12.35 score on a scale	Standard Deviation 22.03
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at Cycle 26	-11.46 score on a scale	Standard Deviation 22.84
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at PT Visit 1	5.25 score on a scale	Standard Deviation 24
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Fatigue Symptom Scale: Change at PT Visit 2	9.70 score on a scale	Standard Deviation 25.01
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at Cycle 3	0.00 score on a scale	Standard Deviation 26.33
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at Cycle 4	0.11 score on a scale	Standard Deviation 25.1
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at PT Visit 2	4.24 score on a scale	Standard Deviation 31.32
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea And Vomiting Scale: Change at Cycle 4	3.56 score on a scale	Standard Deviation 23.76
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea And Vomiting Scale: Change at Cycle 6	2.59 score on a scale	Standard Deviation 21.24
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea And Vomiting Scale: Change at Cycle 8	-0.77 score on a scale	Standard Deviation 20.21
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at Cycle 23	8.33 score on a scale	Standard Deviation 20.49
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at Cycle 24	3.33 score on a scale	Standard Deviation 16.54
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at Cycle 27	3.45 score on a scale	Standard Deviation 16.29
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at Cycle 8	0.47 score on a scale	Standard Deviation 25.27
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Diarrhea Symptom Scale: Change at Cycle 28	2.56 score on a scale	Standard Deviation 16.12
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at Cycle 2	0.29 score on a scale	Standard Deviation 19.72
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at Cycle 4	1.81 score on a scale	Standard Deviation 21.08
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Dyspnoea Symptom Scale: Change at Cycle 8	0.93 score on a scale	Standard Deviation 20.56
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at Cycle 9	-0.51 score on a scale	Standard Deviation 24.75
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at Cycle 26	-4.17 score on a scale	Standard Deviation 20.3
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at Cycle 27	-4.60 score on a scale	Standard Deviation 19.36
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at Cycle 28	-1.28 score on a scale	Standard Deviation 22.07
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at PT Visit 1	-1.32 score on a scale	Standard Deviation 30.81
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at PT Visit 2	3.03 score on a scale	Standard Deviation 31.13
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at Cycle 10	-2.42 score on a scale	Standard Deviation 24.3
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at Cycle 11	-0.22 score on a scale	Standard Deviation 24.84
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at Cycle 13	0.30 score on a scale	Standard Deviation 24.82
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at Cycle 14	-0.98 score on a scale	Standard Deviation 25.02
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at Cycle 15	1.36 score on a scale	Standard Deviation 26.18
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at Cycle 16	0.39 score on a scale	Standard Deviation 25.97
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at Cycle 17	1.35 score on a scale	Standard Deviation 27.28
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at Cycle 18	2.35 score on a scale	Standard Deviation 26.02
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at Cycle 19	-0.51 score on a scale	Standard Deviation 27.73
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at Cycle 20	1.59 score on a scale	Standard Deviation 27.71
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at Cycle 21	-4.94 score on a scale	Standard Deviation 27.78
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at Cycle 22	-4.26 score on a scale	Standard Deviation 23.69
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at Cycle 23	-2.27 score on a scale	Standard Deviation 29.11
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at Cycle 24	-5.83 score on a scale	Standard Deviation 26.03
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at Cycle 26	-2.22 score on a scale	Standard Deviation 26.16
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Financial Difficulties Scale: Change at Cycle 28	-1.28 score on a scale	Standard Deviation 24
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea And Vomiting Scale: Change at Cycle 14	-5.72 score on a scale	Standard Deviation 18.54
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea And Vomiting Scale: Change at Cycle 15	-3.91 score on a scale	Standard Deviation 16.55
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea And Vomiting Scale: Change at Cycle 17	-3.15 score on a scale	Standard Deviation 16.48
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea And Vomiting Scale: Change at Cycle 19	-4.04 score on a scale	Standard Deviation 19.62
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea And Vomiting Scale: Change at Cycle 20	-3.97 score on a scale	Standard Deviation 17.89
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea And Vomiting Scale: Change at Cycle 21	-6.48 score on a scale	Standard Deviation 19.8
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea And Vomiting Scale: Change at Cycle 24	-7.92 score on a scale	Standard Deviation 17.7
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea And Vomiting Scale: Change at Cycle 25	-7.41 score on a scale	Standard Deviation 19.29
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea And Vomiting Scale: Change at Cycle 26	-9.38 score on a scale	Standard Deviation 19.37
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea And Vomiting Scale: Change at Cycle 27	-7.47 score on a scale	Standard Deviation 20.7
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea And Vomiting Scale: Change at Cycle 28	-6.41 score on a scale	Standard Deviation 17.69
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea and Vomiting Scale: Change at PT Visit 1	4.13 score on a scale	Standard Deviation 23.91
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Nausea and Vomiting Scale: Change at PT Visit 2	2.73 score on a scale	Standard Deviation 21.6
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at Cycle 7	-7.46 score on a scale	Standard Deviation 24.79
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Cycle 1 (Baseline)	23.72 score on a scale	Standard Deviation 24.82
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at Cycle 2	-6.38 score on a scale	Standard Deviation 23.58
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at Cycle 3	-7.23 score on a scale	Standard Deviation 25.78
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at Cycle 4	-7.46 score on a scale	Standard Deviation 26.06
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at Cycle 5	-6.25 score on a scale	Standard Deviation 25.42
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at Cycle 6	-7.33 score on a scale	Standard Deviation 24.85
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at Cycle 10	-8.13 score on a scale	Standard Deviation 22.75
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at Cycle 11	-6.34 score on a scale	Standard Deviation 22.97
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at Cycle 12	-5.24 score on a scale	Standard Deviation 25.29
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at Cycle 13	-4.80 score on a scale	Standard Deviation 20.27
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at Cycle 15	-3.74 score on a scale	Standard Deviation 22.77
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at Cycle 17	-5.63 score on a scale	Standard Deviation 22.63
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at Cycle 18	-8.22 score on a scale	Standard Deviation 20.68
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at Cycle 19	-5.05 score on a scale	Standard Deviation 21.48
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at Cycle 20	-6.08 score on a scale	Standard Deviation 19.24
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at Cycle 21	-6.48 score on a scale	Standard Deviation 23.44
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at Cycle 22	-8.51 score on a scale	Standard Deviation 19.62
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at Cycle 24	-10.00 score on a scale	Standard Deviation 17.21
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at Cycle 25	-12.96 score on a scale	Standard Deviation 19.96
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at Cycle 26	-8.33 score on a scale	Standard Deviation 18.45
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at Cycle 27	-5.75 score on a scale	Standard Deviation 21.95
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Pain Symptom Scale: Change at Cycle 28	-9.62 score on a scale	Standard Deviation 19.54
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Cycle 1 (Baseline)	82.05 score on a scale	Standard Deviation 18.32
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at Cycle 2	-3.01 score on a scale	Standard Deviation 15.34
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at Cycle 5	-4.62 score on a scale	Standard Deviation 17.62
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at Cycle 6	-3.84 score on a scale	Standard Deviation 18.65
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at Cycle 7	-3.79 score on a scale	Standard Deviation 19.82
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at Cycle 8	-1.56 score on a scale	Standard Deviation 18.55
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at Cycle 16	-0.08 score on a scale	Standard Deviation 18.18
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at Cycle 18	0.75 score on a scale	Standard Deviation 16.85
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at Cycle 20	0.85 score on a scale	Standard Deviation 16.74
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at Cycle 21	0.25 score on a scale	Standard Deviation 18.18
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at Cycle 22	1.42 score on a scale	Standard Deviation 16.79
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at Cycle 23	0.61 score on a scale	Standard Deviation 19.6
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at Cycle 24	3.00 score on a scale	Standard Deviation 16.47
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at Cycle 25	4.81 score on a scale	Standard Deviation 15.91
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at Cycle 26	-1.88 score on a scale	Standard Deviation 20.69
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at Cycle 27	-3.68 score on a scale	Standard Deviation 19.4
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at Cycle 28	-2.82 score on a scale	Standard Deviation 18.97
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at PT Visit 1	-7.51 score on a scale	Standard Deviation 20.53
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Physical Functional Scale: Change at PT Visit 2	-11.82 score on a scale	Standard Deviation 20.27
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at Cycle 2	4.29 score on a scale	Standard Deviation 23.42
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at Cycle 3	2.86 score on a scale	Standard Deviation 25.03
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at Cycle 4	4.15 score on a scale	Standard Deviation 23.79
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at Cycle 5	3.92 score on a scale	Standard Deviation 23.05
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at Cycle 6	3.61 score on a scale	Standard Deviation 23.13
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at Cycle 7	3.33 score on a scale	Standard Deviation 22.77
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at Cycle 8	5.18 score on a scale	Standard Deviation 23.18
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at Cycle 9	4.68 score on a scale	Standard Deviation 22.99
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at Cycle 10	5.07 score on a scale	Standard Deviation 22.77
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at Cycle 12	5.34 score on a scale	Standard Deviation 24.47
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at Cycle 13	3.83 score on a scale	Standard Deviation 23.78
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at Cycle 14	4.82 score on a scale	Standard Deviation 24.86
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at Cycle 15	1.70 score on a scale	Standard Deviation 24.46
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at Cycle 16	3.04 score on a scale	Standard Deviation 23.77
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at Cycle 17	3.83 score on a scale	Standard Deviation 24.84
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at Cycle 18	2.58 score on a scale	Standard Deviation 27.08
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at Cycle 19	3.97 score on a scale	Standard Deviation 25.43
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at Cycle 20	4.89 score on a scale	Standard Deviation 25.69
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at Cycle 21	5.40 score on a scale	Standard Deviation 24.72
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at Cycle 22	3.19 score on a scale	Standard Deviation 25.57
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at Cycle 23	4.07 score on a scale	Standard Deviation 27.18
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at Cycle 24	2.92 score on a scale	Standard Deviation 30.58
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at Cycle 25	8.10 score on a scale	Standard Deviation 25.39
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at Cycle 26	5.47 score on a scale	Standard Deviation 26.91
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at Cycle 27	1.72 score on a scale	Standard Deviation 28.38
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at Cycle 28	4.81 score on a scale	Standard Deviation 28.98
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at PT Visit 1	-6.14 score on a scale	Standard Deviation 24.97
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Global Health Status Scale: Change at PT Visit 2	-5.68 score on a scale	Standard Deviation 26.57
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Cycle 1 (Baseline)	79.33 score on a scale	Standard Deviation 25.12
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at Cycle 2	-2.82 score on a scale	Standard Deviation 24.35
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at Cycle 3	-4.55 score on a scale	Standard Deviation 28
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at Cycle 4	-5.99 score on a scale	Standard Deviation 26.87
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at Cycle 5	-7.41 score on a scale	Standard Deviation 27.25
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at Cycle 6	-6.03 score on a scale	Standard Deviation 28.51
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at Cycle 7	-5.34 score on a scale	Standard Deviation 26.31
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at Cycle 8	-2.38 score on a scale	Standard Deviation 26.41
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at Cycle 9	-2.47 score on a scale	Standard Deviation 27.29
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at Cycle 10	0.90 score on a scale	Standard Deviation 25.97
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at Cycle 11	-2.69 score on a scale	Standard Deviation 24.94
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at Cycle 12	0.24 score on a scale	Standard Deviation 24.07
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at Cycle 13	-2.40 score on a scale	Standard Deviation 24.91
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at Cycle 14	-1.31 score on a scale	Standard Deviation 25.66
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at Cycle 15	-3.23 score on a scale	Standard Deviation 25.4
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at Cycle 16	-2.35 score on a scale	Standard Deviation 25.48
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at Cycle 17	-3.38 score on a scale	Standard Deviation 25.88
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at Cycle 18	0.23 score on a scale	Standard Deviation 26.05
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at Cycle 19	-0.25 score on a scale	Standard Deviation 23.48
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at Cycle 20	0.79 score on a scale	Standard Deviation 23.46
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at Cycle 21	0.00 score on a scale	Standard Deviation 27.47
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at Cycle 22	1.06 score on a scale	Standard Deviation 22.63
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at Cycle 23	1.14 score on a scale	Standard Deviation 25.01
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at Cycle 24	2.08 score on a scale	Standard Deviation 24.22
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at Cycle 25	4.63 score on a scale	Standard Deviation 26.91
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at Cycle 26	0.52 score on a scale	Standard Deviation 26.6
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at Cycle 27	-4.02 score on a scale	Standard Deviation 29.77
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at Cycle 28	-3.85 score on a scale	Standard Deviation 29.56
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at PT Visit 1	-9.49 score on a scale	Standard Deviation 28.64
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Role Functional Scale: Change at PT Visit 2	-15.45 score on a scale	Standard Deviation 31.82
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Cycle 1 (Baseline)	75.90 score on a scale	Standard Deviation 24.69
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at Cycle 2	-0.44 score on a scale	Standard Deviation 23.09
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at Cycle 3	-2.07 score on a scale	Standard Deviation 25.35
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at Cycle 4	-1.70 score on a scale	Standard Deviation 26.58
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at Cycle 5	-3.26 score on a scale	Standard Deviation 27.24
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at Cycle 6	-1.04 score on a scale	Standard Deviation 27.2
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at Cycle 7	-0.15 score on a scale	Standard Deviation 26
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at Cycle 8	1.08 score on a scale	Standard Deviation 26.49
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at Cycle 9	0.77 score on a scale	Standard Deviation 25.11
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at Cycle 10	2.31 score on a scale	Standard Deviation 25.75
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at Cycle 11	1.94 score on a scale	Standard Deviation 24.39
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at Cycle 12	2.40 score on a scale	Standard Deviation 24.7
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at Cycle 13	2.10 score on a scale	Standard Deviation 25.73
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at Cycle 14	2.12 score on a scale	Standard Deviation 24.89
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at Cycle 15	0.00 score on a scale	Standard Deviation 27.08
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at Cycle 16	0.39 score on a scale	Standard Deviation 25.84
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at Cycle 17	1.58 score on a scale	Standard Deviation 24.39
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at Cycle 18	2.11 score on a scale	Standard Deviation 26.42
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at Cycle 19	3.28 score on a scale	Standard Deviation 21.53
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at Cycle 20	0.79 score on a scale	Standard Deviation 22.88
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at Cycle 21	5.86 score on a scale	Standard Deviation 22
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at Cycle 22	2.84 score on a scale	Standard Deviation 24.16
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at Cycle 23	1.89 score on a scale	Standard Deviation 22.51
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at Cycle 24	4.17 score on a scale	Standard Deviation 24.39
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at Cycle 25	2.78 score on a scale	Standard Deviation 23.4
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at Cycle 26	1.56 score on a scale	Standard Deviation 24.45
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at Cycle 27	-1.72 score on a scale	Standard Deviation 26.85
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at Cycle 28	-0.64 score on a scale	Standard Deviation 24.26
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at PT Visit 1	-3.80 score on a scale	Standard Deviation 28.74
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Social Functional Scale: Change at PT Visit 2	-8.48 score on a scale	Standard Deviation 28.98
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Cycle 1 (Baseline)	25.41 score on a scale	Standard Deviation 28.81
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at Cycle 2	-0.39 score on a scale	Standard Deviation 28.27
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at Cycle 3	-3.48 score on a scale	Standard Deviation 30.14
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at Cycle 4	-3.62 score on a scale	Standard Deviation 30.4
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at Cycle 5	-2.66 score on a scale	Standard Deviation 30.17
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at Cycle 6	-5.58 score on a scale	Standard Deviation 32.53
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at Cycle 9	-6.12 score on a scale	Standard Deviation 30.32
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at Cycle 10	-4.42 score on a scale	Standard Deviation 28.79
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at Cycle 11	-5.81 score on a scale	Standard Deviation 27.69
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at Cycle 12	-6.43 score on a scale	Standard Deviation 26.49
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at Cycle 13	-5.11 score on a scale	Standard Deviation 24.29
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at Cycle 14	-7.84 score on a scale	Standard Deviation 24.45
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at Cycle 15	-5.10 score on a scale	Standard Deviation 21.59
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at Cycle 16	-4.31 score on a scale	Standard Deviation 26.62
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at Cycle 17	-5.41 score on a scale	Standard Deviation 26.48
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at Cycle 18	-8.45 score on a scale	Standard Deviation 20.09
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at Cycle 19	-7.58 score on a scale	Standard Deviation 22.49
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at Cycle 20	-5.29 score on a scale	Standard Deviation 25.55
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at Cycle 21	-4.94 score on a scale	Standard Deviation 27.02
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at Cycle 22	-7.80 score on a scale	Standard Deviation 19.92
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at Cycle 23	-6.06 score on a scale	Standard Deviation 23.04
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at Cycle 24	-7.50 score on a scale	Standard Deviation 21.99
Placebo + Trastuzumab + Chemotherapy	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score	Insomnia Symptom Scale: Change at Cycle 25	-8.33 score on a scale	Standard Deviation 26.87

Secondary

Cmax of Trastuzumab

Time frame: Post-dose (0.5 hour after end of 30-60 minutes infusion) on Day 1 of Cycles 1, 2, 4, and 8 (1 cycle = 21 days)

Population: The pharmacokinetic analysis included all participants who were treated with study medication and who had at least one measurable concentration of pertuzumab or trastuzumab. Data are reported for evaluable participants.

Arm	Measure	Group	Value (MEAN)	Dispersion
Pertuzumab + Trastuzumab + Chemotherapy	Cmax of Trastuzumab	Cycle 1	142 μg/mL	Standard Deviation 86.8
Pertuzumab + Trastuzumab + Chemotherapy	Cmax of Trastuzumab	Cycle 2	120 μg/mL	Standard Deviation 46.6
Pertuzumab + Trastuzumab + Chemotherapy	Cmax of Trastuzumab	Cycle 4	127 μg/mL	Standard Deviation 50.9
Pertuzumab + Trastuzumab + Chemotherapy	Cmax of Trastuzumab	Cycle 8	130 μg/mL	Standard Deviation 50.8
Placebo + Trastuzumab + Chemotherapy	Cmax of Trastuzumab	Cycle 8	147 μg/mL	Standard Deviation 90.2
Placebo + Trastuzumab + Chemotherapy	Cmax of Trastuzumab	Cycle 1	139 μg/mL	Standard Deviation 58.6
Placebo + Trastuzumab + Chemotherapy	Cmax of Trastuzumab	Cycle 4	129 μg/mL	Standard Deviation 58.1
Placebo + Trastuzumab + Chemotherapy	Cmax of Trastuzumab	Cycle 2	120 μg/mL	Standard Deviation 44.3

Secondary

Cmin of Trastuzumab

Time frame: Pre-dose (0-6 hours before infusion) on Day 1 of Cycles 1, 2, 3, 4, 6, and 8 (1 cycle = 21 days)

Arm	Measure	Group	Value (MEAN)	Dispersion
Pertuzumab + Trastuzumab + Chemotherapy	Cmin of Trastuzumab	Cycle 1	NA μg/mL	—
Pertuzumab + Trastuzumab + Chemotherapy	Cmin of Trastuzumab	Cycle 2	15.4 μg/mL	Standard Deviation 11.3
Pertuzumab + Trastuzumab + Chemotherapy	Cmin of Trastuzumab	Cycle 3	19.9 μg/mL	Standard Deviation 13.4
Pertuzumab + Trastuzumab + Chemotherapy	Cmin of Trastuzumab	Cycle 4	22.9 μg/mL	Standard Deviation 12.7
Pertuzumab + Trastuzumab + Chemotherapy	Cmin of Trastuzumab	Cycle 6	26.3 μg/mL	Standard Deviation 14.8
Pertuzumab + Trastuzumab + Chemotherapy	Cmin of Trastuzumab	Cycle 8	32.7 μg/mL	Standard Deviation 15
Placebo + Trastuzumab + Chemotherapy	Cmin of Trastuzumab	Cycle 6	29.8 μg/mL	Standard Deviation 21.9
Placebo + Trastuzumab + Chemotherapy	Cmin of Trastuzumab	Cycle 1	NA μg/mL	—
Placebo + Trastuzumab + Chemotherapy	Cmin of Trastuzumab	Cycle 4	24.1 μg/mL	Standard Deviation 19
Placebo + Trastuzumab + Chemotherapy	Cmin of Trastuzumab	Cycle 2	17.2 μg/mL	Standard Deviation 15.4
Placebo + Trastuzumab + Chemotherapy	Cmin of Trastuzumab	Cycle 8	37.4 μg/mL	Standard Deviation 20.3
Placebo + Trastuzumab + Chemotherapy	Cmin of Trastuzumab	Cycle 3	20.7 μg/mL	Standard Deviation 15.2

Secondary

Duration of Objective Response, as Determined by Investigator According to RECIST v1.1 Criteria

Duration of objective response is defined as the time from first occurrence of documented objective response to documented disease progression, as determined by the investigator using RECIST v1.1, or death from any cause. Objective response: PR or CR occurring on 2 consecutive occasions ≥4 weeks apart. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR: disappearance of all target lesions. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline; an absolute increase of at least 5 mm in the sum of diameters of target lesions; the appearance of one or more new lesions. Measurable disease defined as tumor lesions with a minimum size of: 10 mm by CT or MRI scan; 10 mm caliper measurement by clinical examination; 20 mm by chest X-ray. For a malignant lymph node, it must be ≥15 mm in short axis when assessed by CT scan.

Time frame: Baseline to death or progressive disease (PD), whichever occurred first (Median [full range] duration of follow-up in Pertuzumab vs. Placebo arms for Primary Analysis: 24.9 [0-41] vs. 21.3 [0-39] months; Final Analysis: 50.4 [0-70] vs. 47.4 [0-66] months)

Population: The participants with measurable disease at baseline who achieved a documented objective response, according to RECIST v1.1 criteria.

Arm	Measure	Group	Value (MEDIAN)
Pertuzumab + Trastuzumab + Chemotherapy	Duration of Objective Response, as Determined by Investigator According to RECIST v1.1 Criteria	Final Analysis	10.2 months
Pertuzumab + Trastuzumab + Chemotherapy	Duration of Objective Response, as Determined by Investigator According to RECIST v1.1 Criteria	Primary Analysis	10.2 months
Placebo + Trastuzumab + Chemotherapy	Duration of Objective Response, as Determined by Investigator According to RECIST v1.1 Criteria	Final Analysis	8.4 months
Placebo + Trastuzumab + Chemotherapy	Duration of Objective Response, as Determined by Investigator According to RECIST v1.1 Criteria	Primary Analysis	8.4 months

Comparison: Primary Analysis95% CI: [0.64, 1.06]

Comparison: Final Analysis95% CI: [0.62, 0.98]

Secondary

Final Analysis of the Percentage of Participants With Overall Objective Response, as Determined by the Investigator According to RECIST v1.1 Criteria

The overall objective response rate was defined as the percentage of participants with partial response (PR) or complete response (CR) occurring on two consecutive occasions ≥4 weeks apart, as determined by the investigator using RECIST v1.1. Tumor assessments with computed tomography (CT) or magnetic resonance imaging (MRI) scans of the chest, abdomen, and pelvis were performed every 9 weeks. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR: disappearance of all target lesions. Measurable disease is defined as tumor lesions measured in at least one dimension (longest diameter in plane of measurement) with a minimum size of: 10 mm by CT or MRI scan; 10 mm caliper measurement by clinical examination; 20 mm by chest X-ray. For a malignant lymph node to be considered pathologically enlarged and measurable, it must be greater than or equal to (≥) 15 mm in short axis when assessed by CT scan.

Time frame: Baseline up to death or progressive disease, whichever occurred first (Median [full range] duration of follow-up in Pertuzumab vs. Placebo arms for Final Analysis: 50.4 [0-70] months vs. 47.4 [0-66] months)

Population: The subset of participants with measurable disease at baseline, according to RECIST v1.1 criteria.

Arm	Measure	Group	Value (NUMBER)
Pertuzumab + Trastuzumab + Chemotherapy	Final Analysis of the Percentage of Participants With Overall Objective Response, as Determined by the Investigator According to RECIST v1.1 Criteria	Progressive Disease (PD)	4.8 Percentage of participants
Pertuzumab + Trastuzumab + Chemotherapy	Final Analysis of the Percentage of Participants With Overall Objective Response, as Determined by the Investigator According to RECIST v1.1 Criteria	Objective Response (CR + PR)	57.0 Percentage of participants
Pertuzumab + Trastuzumab + Chemotherapy	Final Analysis of the Percentage of Participants With Overall Objective Response, as Determined by the Investigator According to RECIST v1.1 Criteria	Complete Response (CR)	5.7 Percentage of participants
Pertuzumab + Trastuzumab + Chemotherapy	Final Analysis of the Percentage of Participants With Overall Objective Response, as Determined by the Investigator According to RECIST v1.1 Criteria	Partial Response (PR)	51.3 Percentage of participants
Pertuzumab + Trastuzumab + Chemotherapy	Final Analysis of the Percentage of Participants With Overall Objective Response, as Determined by the Investigator According to RECIST v1.1 Criteria	Stable Disease (SD)	27.6 Percentage of participants
Pertuzumab + Trastuzumab + Chemotherapy	Final Analysis of the Percentage of Participants With Overall Objective Response, as Determined by the Investigator According to RECIST v1.1 Criteria	Not Evaluable/Missing	10.5 Percentage of participants
Placebo + Trastuzumab + Chemotherapy	Final Analysis of the Percentage of Participants With Overall Objective Response, as Determined by the Investigator According to RECIST v1.1 Criteria	Progressive Disease (PD)	8.2 Percentage of participants
Placebo + Trastuzumab + Chemotherapy	Final Analysis of the Percentage of Participants With Overall Objective Response, as Determined by the Investigator According to RECIST v1.1 Criteria	Partial Response (PR)	46.6 Percentage of participants
Placebo + Trastuzumab + Chemotherapy	Final Analysis of the Percentage of Participants With Overall Objective Response, as Determined by the Investigator According to RECIST v1.1 Criteria	Not Evaluable/Missing	10.5 Percentage of participants
Placebo + Trastuzumab + Chemotherapy	Final Analysis of the Percentage of Participants With Overall Objective Response, as Determined by the Investigator According to RECIST v1.1 Criteria	Objective Response (CR + PR)	48.6 Percentage of participants
Placebo + Trastuzumab + Chemotherapy	Final Analysis of the Percentage of Participants With Overall Objective Response, as Determined by the Investigator According to RECIST v1.1 Criteria	Stable Disease (SD)	32.7 Percentage of participants
Placebo + Trastuzumab + Chemotherapy	Final Analysis of the Percentage of Participants With Overall Objective Response, as Determined by the Investigator According to RECIST v1.1 Criteria	Complete Response (CR)	2.0 Percentage of participants

Comparison: Final Analysis of Objective Response Rate95% CI: [0.89, 15.91]

Comparison: Final Analysis of Objective Response Rate95% CI: [1.04, 1.89]

Secondary

Maximum Serum Concentration (Cmax) of Pertuzumab

Time frame: Post-dose (0.5 hour after end of 30-60 minutes infusion) on Day 1 of Cycles 1, 2, 4, and 8 (1 cycle = 21 days)

Arm	Measure	Group	Value (MEAN)	Dispersion
Pertuzumab + Trastuzumab + Chemotherapy	Maximum Serum Concentration (Cmax) of Pertuzumab	Cycle 1	258 micrograms per milliliter (μg/mL)	Standard Deviation 90.3
Pertuzumab + Trastuzumab + Chemotherapy	Maximum Serum Concentration (Cmax) of Pertuzumab	Cycle 2	288 micrograms per milliliter (μg/mL)	Standard Deviation 83.7
Pertuzumab + Trastuzumab + Chemotherapy	Maximum Serum Concentration (Cmax) of Pertuzumab	Cycle 4	341 micrograms per milliliter (μg/mL)	Standard Deviation 111
Pertuzumab + Trastuzumab + Chemotherapy	Maximum Serum Concentration (Cmax) of Pertuzumab	Cycle 8	371 micrograms per milliliter (μg/mL)	Standard Deviation 127

Secondary

Minimum Serum Concentration (Cmin) of Pertuzumab

Time frame: Pre-dose (0-6 hours before infusion) on Day 1 of Cycles 1, 2, 3, 4, 6, and 8 (1 cycle = 21 days)

Arm	Measure	Group	Value (MEAN)	Dispersion
Pertuzumab + Trastuzumab + Chemotherapy	Minimum Serum Concentration (Cmin) of Pertuzumab	Cycle 1	NA μg/mL	—
Pertuzumab + Trastuzumab + Chemotherapy	Minimum Serum Concentration (Cmin) of Pertuzumab	Cycle 2	42.4 μg/mL	Standard Deviation 24.8
Pertuzumab + Trastuzumab + Chemotherapy	Minimum Serum Concentration (Cmin) of Pertuzumab	Cycle 3	74.0 μg/mL	Standard Deviation 40.9
Pertuzumab + Trastuzumab + Chemotherapy	Minimum Serum Concentration (Cmin) of Pertuzumab	Cycle 4	90.4 μg/mL	Standard Deviation 42.4
Pertuzumab + Trastuzumab + Chemotherapy	Minimum Serum Concentration (Cmin) of Pertuzumab	Cycle 6	114 μg/mL	Standard Deviation 51.8
Pertuzumab + Trastuzumab + Chemotherapy	Minimum Serum Concentration (Cmin) of Pertuzumab	Cycle 8	142 μg/mL	Standard Deviation 67.9

Secondary

Number of Participants With Symptomatic or Asymptomatic Left Ventricular Systolic Dysfunction (LVSD)

The number and percentage of participants with symptomatic left ventricular systolic dysfunction (LVSD) and asymptomatic LVSD events (defined as a left ventricular ejection fraction \[LVEF\] ≥10% decrease from baseline to an absolute value \<50%) at any time during the study was summarized by treatment arm.

Time frame: From Baseline until end of post-treatment follow-up (up to 70 months)

Population: The safety population included all participants who received any amount of any study medication. Those who received any amount of pertuzumab were included in the pertuzumab arm; all other treated participants were included in the placebo arm.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Pertuzumab + Trastuzumab + Chemotherapy	Number of Participants With Symptomatic or Asymptomatic Left Ventricular Systolic Dysfunction (LVSD)	Asymptomatic LVSD	20 Participants
Pertuzumab + Trastuzumab + Chemotherapy	Number of Participants With Symptomatic or Asymptomatic Left Ventricular Systolic Dysfunction (LVSD)	Symptomatic LVSD	3 Participants
Placebo + Trastuzumab + Chemotherapy	Number of Participants With Symptomatic or Asymptomatic Left Ventricular Systolic Dysfunction (LVSD)	Symptomatic LVSD	1 Participants
Placebo + Trastuzumab + Chemotherapy	Number of Participants With Symptomatic or Asymptomatic Left Ventricular Systolic Dysfunction (LVSD)	Asymptomatic LVSD	18 Participants

Secondary

Overview of Safety: Number of Participants With at Least One Adverse Event, Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.03

An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. The investigator graded all AEs for severity per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.03; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE.

Time frame: From Baseline until end of post-treatment follow-up (up to 70 months)

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Pertuzumab + Trastuzumab + Chemotherapy	Overview of Safety: Number of Participants With at Least One Adverse Event, Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.03	Any Adverse Event (AE)	381 Participants
Pertuzumab + Trastuzumab + Chemotherapy	Overview of Safety: Number of Participants With at Least One Adverse Event, Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.03	AE with Fatal Outcome	27 Participants
Pertuzumab + Trastuzumab + Chemotherapy	Overview of Safety: Number of Participants With at Least One Adverse Event, Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.03	Serious AE	178 Participants
Pertuzumab + Trastuzumab + Chemotherapy	Overview of Safety: Number of Participants With at Least One Adverse Event, Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.03	Grade 3-5 AE	310 Participants
Pertuzumab + Trastuzumab + Chemotherapy	Overview of Safety: Number of Participants With at Least One Adverse Event, Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.03	AE Leading to Pertuz/Pbo & Trastuz Discontinuation	48 Participants
Pertuzumab + Trastuzumab + Chemotherapy	Overview of Safety: Number of Participants With at Least One Adverse Event, Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.03	AE Leading to Dose Interruption &/or Dose Delay	110 Participants
Placebo + Trastuzumab + Chemotherapy	Overview of Safety: Number of Participants With at Least One Adverse Event, Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.03	AE Leading to Pertuz/Pbo & Trastuz Discontinuation	46 Participants
Placebo + Trastuzumab + Chemotherapy	Overview of Safety: Number of Participants With at Least One Adverse Event, Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.03	Any Adverse Event (AE)	385 Participants
Placebo + Trastuzumab + Chemotherapy	Overview of Safety: Number of Participants With at Least One Adverse Event, Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.03	Grade 3-5 AE	288 Participants
Placebo + Trastuzumab + Chemotherapy	Overview of Safety: Number of Participants With at Least One Adverse Event, Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.03	AE with Fatal Outcome	31 Participants
Placebo + Trastuzumab + Chemotherapy	Overview of Safety: Number of Participants With at Least One Adverse Event, Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.03	AE Leading to Dose Interruption &/or Dose Delay	94 Participants
Placebo + Trastuzumab + Chemotherapy	Overview of Safety: Number of Participants With at Least One Adverse Event, Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.03	Serious AE	156 Participants

Secondary

Percentage of Participants With Clinical Benefit, as Determined by the Investigator According to RECIST v1.1 Criteria

The clinical benefit rate was defined as best response of complete response (CR) or partial response (PR) or stable disease (SD) for 6 weeks or longer, as determined by the investigator using RECIST v1.1. CR: disappearance of all target lesions. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression, taking as reference the smallest sum diameters while on study. Measurable disease is defined as tumor lesions measured in at least one dimension (longest diameter in plane of measurement) with a minimum size of: 10 mm by CT or MRI scan; 10 mm caliper measurement by clinical examination; 20 mm by chest X-ray. For a malignant lymph node to be considered pathologically enlarged and measurable, it must be \>/=15 mm in short axis when assessed by CT scan. The clinical benefit rate was not updated at the final analysis.

Time frame: Baseline up to death or progressive disease, whichever occurred first (Median [full range] duration of follow-up in Pertuzumab vs. Placebo arms for Primary Analysis: 24.9 [0-41] months vs. 21.3 [0-39] months)

Population: The subset of participants with measurable disease at baseline, according to RECIST v1.1 criteria.

Arm	Measure	Value (NUMBER)
Pertuzumab + Trastuzumab + Chemotherapy	Percentage of Participants With Clinical Benefit, as Determined by the Investigator According to RECIST v1.1 Criteria	84.6 percentage of participants
Placebo + Trastuzumab + Chemotherapy	Percentage of Participants With Clinical Benefit, as Determined by the Investigator According to RECIST v1.1 Criteria	81.3 percentage of participants

95% CI: [-2.34, 9.07]

95% CI: [0.86, 1.88]

Secondary

Primary Analysis of the Percentage of Participants With Overall Objective Response, as Determined by the Investigator According to RECIST v1.1 Criteria

Population: The subset of participants with measurable disease at baseline, according to RECIST v1.1 criteria.

Arm	Measure	Group	Value (NUMBER)
Pertuzumab + Trastuzumab + Chemotherapy	Primary Analysis of the Percentage of Participants With Overall Objective Response, as Determined by the Investigator According to RECIST v1.1 Criteria	Objective Response (CR + PR)	56.7 Percentage of participants
Pertuzumab + Trastuzumab + Chemotherapy	Primary Analysis of the Percentage of Participants With Overall Objective Response, as Determined by the Investigator According to RECIST v1.1 Criteria	Stable Disease (SD)	27.9 Percentage of participants
Pertuzumab + Trastuzumab + Chemotherapy	Primary Analysis of the Percentage of Participants With Overall Objective Response, as Determined by the Investigator According to RECIST v1.1 Criteria	Complete Response (CR)	5.1 Percentage of participants
Pertuzumab + Trastuzumab + Chemotherapy	Primary Analysis of the Percentage of Participants With Overall Objective Response, as Determined by the Investigator According to RECIST v1.1 Criteria	Progressive Disease (PD)	4.8 Percentage of participants
Pertuzumab + Trastuzumab + Chemotherapy	Primary Analysis of the Percentage of Participants With Overall Objective Response, as Determined by the Investigator According to RECIST v1.1 Criteria	Partial Response (PR)	51.6 Percentage of participants
Pertuzumab + Trastuzumab + Chemotherapy	Primary Analysis of the Percentage of Participants With Overall Objective Response, as Determined by the Investigator According to RECIST v1.1 Criteria	Not Evaluable/Missing	10.5 Percentage of participants
Placebo + Trastuzumab + Chemotherapy	Primary Analysis of the Percentage of Participants With Overall Objective Response, as Determined by the Investigator According to RECIST v1.1 Criteria	Partial Response (PR)	47.4 Percentage of participants
Placebo + Trastuzumab + Chemotherapy	Primary Analysis of the Percentage of Participants With Overall Objective Response, as Determined by the Investigator According to RECIST v1.1 Criteria	Not Evaluable/Missing	10.8 Percentage of participants
Placebo + Trastuzumab + Chemotherapy	Primary Analysis of the Percentage of Participants With Overall Objective Response, as Determined by the Investigator According to RECIST v1.1 Criteria	Complete Response (CR)	0.9 Percentage of participants
Placebo + Trastuzumab + Chemotherapy	Primary Analysis of the Percentage of Participants With Overall Objective Response, as Determined by the Investigator According to RECIST v1.1 Criteria	Objective Response (CR + PR)	48.3 Percentage of participants
Placebo + Trastuzumab + Chemotherapy	Primary Analysis of the Percentage of Participants With Overall Objective Response, as Determined by the Investigator According to RECIST v1.1 Criteria	Stable Disease (SD)	33.0 Percentage of participants
Placebo + Trastuzumab + Chemotherapy	Primary Analysis of the Percentage of Participants With Overall Objective Response, as Determined by the Investigator According to RECIST v1.1 Criteria	Progressive Disease (PD)	8.0 Percentage of participants

Comparison: Primary Analysis of Objective Response Rate95% CI: [0.89, 15.91]

Comparison: Primary Analysis of Objective Response Rate95% CI: [1.04, 1.89]

Secondary

Progression-Free Survival, as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Criteria

Progression-free survival (PFS) is defined as the time from randomization to the first occurrence of progressive disease (PD), as determined by the investigator using RECIST v1.1, or death from any cause, whichever occurred first. Tumor assessments with CT or MRI scans of the chest, abdomen, and pelvis were performed every 9 weeks. Participants without documented PD or death were censored at the tumor assessment date for which the participant was last known to be progression-free. Participants who did not have any post-baseline tumor assessment data were censored at the date of randomization plus 1 day. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline; an absolute increase of at least 5 millimeters (mm) in the sum of diameters of target lesions; the appearance of one or more new lesions.

Population: The ITT population included all randomized participants, regardless of whether study medication was received.

Arm	Measure	Group	Value (MEDIAN)
Pertuzumab + Trastuzumab + Chemotherapy	Progression-Free Survival, as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Criteria	Primary Analysis	8.5 months
Pertuzumab + Trastuzumab + Chemotherapy	Progression-Free Survival, as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Criteria	Final Analysis	8.5 months
Placebo + Trastuzumab + Chemotherapy	Progression-Free Survival, as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Criteria	Primary Analysis	7.0 months
Placebo + Trastuzumab + Chemotherapy	Progression-Free Survival, as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Criteria	Final Analysis	7.2 months

Comparison: Primary Analysis95% CI: [0.62, 0.86]

Comparison: Final Analysis95% CI: [0.62, 0.85]

Source: ClinicalTrials.gov · Data processed: Mar 5, 2026

A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer

Conditions

Brief summary

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Pre-assignment details

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Overall Survival

Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score

Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score

Cmax of Trastuzumab

Cmin of Trastuzumab

Duration of Objective Response, as Determined by Investigator According to RECIST v1.1 Criteria

Final Analysis of the Percentage of Participants With Overall Objective Response, as Determined by the Investigator According to RECIST v1.1 Criteria

Maximum Serum Concentration (Cmax) of Pertuzumab

Minimum Serum Concentration (Cmin) of Pertuzumab

Number of Participants With Symptomatic or Asymptomatic Left Ventricular Systolic Dysfunction (LVSD)

Overview of Safety: Number of Participants With at Least One Adverse Event, Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.03

Percentage of Participants With Clinical Benefit, as Determined by the Investigator According to RECIST v1.1 Criteria

Primary Analysis of the Percentage of Participants With Overall Objective Response, as Determined by the Investigator According to RECIST v1.1 Criteria

Progression-Free Survival, as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Criteria